GSK3A
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O14545 | T323 | Sugiyama | TRAFD1 FLN29 | ELLIDHQTSCNPSRALPsLNtGsssPRGVEEPDVIFQNFLQ |
| O15067 | S1062 | Sugiyama | PFAS KIAA0361 | SYCLPPTFPKAsVPREPGGPsPRVAILREEGSNGDREMADA |
| O15084 | S1007 | SIGNOR|EPSD|PSP | ANKRD28 KIAA0379 | ssssPLssLTFNAINRYTNTsKtVsFEALPIMRNEPSSYCS |
| O15085 | S1457 | Sugiyama | ARHGEF11 KIAA0380 | NRLKDMELAHRELLKsLGGEssGGttPVGSFHTEAARWTDG |
| O15085 | S1458 | Sugiyama | ARHGEF11 KIAA0380 | RLKDMELAHRELLKsLGGEssGGttPVGSFHTEAARWTDGs |
| O15085 | T1462 | Sugiyama | ARHGEF11 KIAA0380 | MELAHRELLKsLGGEssGGttPVGSFHTEAARWTDGsLsPP |
| O43432 | S1409 | Sugiyama | EIF4G3 | EGEDVHNFLLEQKLDFIEsDsPCssEALSKKELSAEELYKR |
| O43432 | S1412 | Sugiyama | EIF4G3 | DVHNFLLEQKLDFIEsDsPCssEALSKKELSAEELYKRLEK |
| O43852 | S261 | Sugiyama | CALU | RDKNRDGKMDKEEtKDWILPsDyDHAEAEARHLVyEsDQNK |
| O43852 | T65 | Sugiyama | CALU | FDyDHDAFLGAEEAKtFDQLtPEEsKERLGKIVSKIDGDKD |
| O60333 | T647 | Sugiyama | KIF1B KIAA0591 KIAA1448 | GKNHVFRFNHPEQARAEREKtPsAEtPsEPVDWTFAQRELL |
| O60333 | T652 | Sugiyama | KIF1B KIAA0591 KIAA1448 | FRFNHPEQARAEREKtPsAEtPsEPVDWTFAQRELLEKQGI |
| O60701 | T185 | Sugiyama | UGDH | EGTAIKDLKNPDRVLIGGDEtPEGQRAVQALCAVYEHWVPR |
| O75030 | S405 | SIGNOR | MITF BHLHE32 | NRHLLLRIQELEMQARAHGLsLIPsTGLCsPDLVNRIIKQE |
| O75581 | S1490 | SIGNOR|PSP | LRP6 | SSSSssTKGtYFPAILNPPPsPAtERsHYTMEFGYSsNsPs |
| O75581 | S1544 | EPSD|PSP | LRP6 | HFAPPtTPCSTDVCDsDyAPsRRMtSVATAKGYTSDLNyDS |
| O75581 | S1607 | PSP | LRP6 | CPPsPYTERSYSHHLYPPPPsPCTDss______________ |
| O75581 | T1572 | PSP | LRP6 | TAKGYTSDLNyDSEPVPPPPtPRSQYLSAEENyESCPPsPY |
| O94979 | S799 | Sugiyama | SEC31A KIAA0905 SEC31L1 HSPC275 HSPC334 | IMQLRDRLCRAQGEPVAGHEsPKIPyEKQQLPKGRPGPVAG |
| O95359 | S2317 | Sugiyama | TACC2 | MPLRRPKMKKtPEKLDNtPAsPPRsPAEPNDIPIAKGTYTF |
| O95359 | S2321 | Sugiyama | TACC2 | RPKMKKtPEKLDNtPAsPPRsPAEPNDIPIAKGTYTFDIDK |
| P00558 | T168 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | EAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNLPQKAGGF |
| P01106 | T73 | PSP | MYC BHLHE39 | SELQPPAPSEDIWKKFELLPtPPLsPsRRsGLCsPSyVAVT |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04406 | S333 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | WyDNEFGysNRVVDLMAHMAsKE__________________ |
| P04637 | S33 | ELM | TP53 P53 | PLsQEtFsDLWKLLPENNVLsPLPsQAMDDLMLsPDDIEQW |
| P05412 | S243 | GPS6|SIGNOR|ELM|EPSD | JUN | QALKEEPQtVPEMPGEtPPLsPIDMEsQERIKAERKRMRNR |
| P05412 | S249 | SIGNOR | JUN | PQtVPEMPGEtPPLsPIDMEsQERIKAERKRMRNRIAASKC |
| P05412 | T239 | GPS6|SIGNOR|ELM|EPSD | JUN | HPRLQALKEEPQtVPEMPGEtPPLsPIDMEsQERIKAERKR |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07205 | T168 | Sugiyama | PGK2 PGKB | EAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNLPHKASGF |
| P07942 | T1141 | Sugiyama | LAMB1 | FWGDPDVECRACDCDPRGIEtPQCDQSTGQCVCVEGVEGPR |
| P08195 | S607 | Sugiyama | SLC3A2 MDU1 | ASLPAKADLLLstQPGREEGsPLELERLKLEPHEGLLLRFP |
| P10636 | S235 | EPSD | MAPT MAPTL MTBT1 TAU | KEEVDEDRDVDESsPQDsPPsKAsPAQDGRPPQTAAREATS |
| P10636 | S579 | SIGNOR | MAPT MAPTL MTBT1 TAU | RLQTAPVPMPDLKNVKsKIGstENLKHQPGGGKVQIINKKL |
| P10636 | S641 | SIGNOR|EPSD | MAPT MAPTL MTBT1 TAU | GsVQIVyKPVDLSKVTsKCGsLGNIHHKPGGGQVEVKSEKL |
| P10809 | S225 | Sugiyama | HSPD1 HSP60 | KtLNDELEIIEGMKFDRGyIsPyFINtsKGQKCEFQDAyVL |
| P10809 | T231 | Sugiyama | HSPD1 HSP60 | LEIIEGMKFDRGyIsPyFINtsKGQKCEFQDAyVLLsEKKI |
| P10809 | T455 | Sugiyama | HSPD1 HSP60 | GIVLGGGCALLRCIPALDsLtPANEDQKIGIEIIKRTLKIP |
| P10809 | Y227 | Sugiyama | HSPD1 HSP60 | LNDELEIIEGMKFDRGyIsPyFINtsKGQKCEFQDAyVLLs |
| P11142 | T37 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | CVGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKN |
| P11586 | T128 | Sugiyama | MTHFD1 MTHFC MTHFD | SINTEEVINAIAPEKDVDGLtsINAGKLARGDLNDCFIPCt |
| P13051 | S64 | SIGNOR|EPSD|PSP | UNG DGU UNG1 UNG15 | AAIPAKKAPAGQEEPGtPPssPLsAEQLDRIQRNKAAALLR |
| P13051 | T60 | SIGNOR|EPSD|PSP | UNG DGU UNG1 UNG15 | SGDAAAIPAKKAPAGQEEPGtPPssPLsAEQLDRIQRNKAA |
| P13807 | S641 | SIGNOR | GYS1 GYS | FTYEPNEADAAQGyRyPRPAsVPPsPsLsRHssPHQsEDEE |
| P13861 | S48 | Sugiyama | PRKAR2A PKR2 PRKAR2 | DLVEFAVEYFTRLREARAPAsVLPAAtPRQsLGHPPPEPGP |
| P13861 | T54 | Sugiyama | PRKAR2A PKR2 PRKAR2 | VEYFTRLREARAPAsVLPAAtPRQsLGHPPPEPGPDRVADA |
| P14618 | S37 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | QLHAAMADTFLEHMCRLDIDsPPItARNtGIICtIGPAsRs |
| P14618 | S55 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | IDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMNVARLN |
| P14618 | T41 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | AMADTFLEHMCRLDIDsPPItARNtGIICtIGPAsRsVEtL |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P16070 | T47 | Sugiyama | CD44 LHR MDU2 MDU3 MIC4 | TCRFAGVFHVEKNGRYsIsRtEAADLCKAFNSTLPTMAQME |
| P16220 | S129 | ELM | CREB1 | KRREILsRRPsYRKILNDLssDAPGVPRIEEEKsEEETSAP |
| P17661 | S28 | PSP | DES | sQRVssYRRtFGGAPGFPLGsPLssPVFPRAGFGsKGssss |
| P17661 | S32 | PSP | DES | ssYRRtFGGAPGFPLGsPLssPVFPRAGFGsKGssssVTSR |
| P17812 | S571 | EPSD|Sugiyama | CTPS1 CTPS | LSHYLQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD |
| P17812 | S573 | Sugiyama | CTPS1 CTPS | HYLQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD__ |
| P17812 | S575 | Sugiyama | CTPS1 CTPS | LQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD____ |
| P18669 | S31 | Sugiyama | PGAM1 PGAMA CDABP0006 | HGEsAWNLENRFsGWyDADLsPAGHEEAKRGGQALRDAGyE |
| P20749 | S402 | SIGNOR|EPSD|PSP | BCL3 BCL4 D19S37 | SPESSSRLSSNGLLSASPSSsPSQsPPRDPPGFPMAPPNFF |
| P20749 | S406 | SIGNOR|EPSD|PSP | BCL3 BCL4 D19S37 | SSRLSSNGLLSASPSSsPSQsPPRDPPGFPMAPPNFFLPSP |
| P22234 | S27 | Sugiyama | PAICS ADE2 AIRC PAIS | LNIGKKLYEGKtKEVyELLDsPGKVLLQsKDQItAGNAARK |
| P22415 | S186 | EPSD | USF1 BHLHB11 USF | PQEVLQGGSQRSIAPRTHPYsPKSEAPRTTRDEKRRAQHNE |
| P22415 | T153 | EPSD | USF1 BHLHB11 USF | SGSTAAVVTTQGSEALLGQAtPPGTGQFFVMMSPQEVLQGG |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P23246 | T687 | SIGNOR | SFPQ PSF | FGQGGAGPVGGQGPRGMGPGtPAGyGRGREEYEGPNKKPRF |
| P23396 | T220 | Sugiyama | RPS3 OK/SW-cl.26 | PKKPLPDHVsIVEPKDEILPttPIsEQKGGKPEPPAMPQPV |
| P23396 | T221 | Sugiyama | RPS3 OK/SW-cl.26 | KKPLPDHVsIVEPKDEILPttPIsEQKGGKPEPPAMPQPVP |
| P24071 | S284 | SIGNOR | FCAR CD89 | AEPSWSQQMCQPGLTFARTPsVCK_________________ |
| P24385 | T286 | ELM | CCND1 BCL1 PRAD1 | MDPKAAEEEEEEEEEVDLACtPtDVRDVDI___________ |
| P24864 | T395 | GPS6|ELM|EPSD|PSP | CCNE1 CCNE | AKKAMLsEQNRAsPLPsGLLtPPQsGKKQSSGPEMA_____ |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27695 | S135 | Sugiyama | APEX1 APE APE1 APEX APX HAP1 REF1 | SHQYWSAPsDKEGysGVGLLsRQCPLKVsyGIGDEEHDQEG |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P31749 | T312 | SIGNOR|EPSD|PSP | AKT1 PKB RAC | DFGLCKEGIKDGAtMKtFCGtPEyLAPEVLEDNDyGRAVDW |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P34897 | S417 | Sugiyama | SHMT2 | ERVLELVSITANKNTCPGDRsAItPGGLRLGAPALtSRQFR |
| P34897 | T420 | Sugiyama | SHMT2 | LELVSITANKNTCPGDRsAItPGGLRLGAPALtSRQFREDD |
| P34931 | T39 | Sugiyama | HSPA1L | CVGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKN |
| P35222 | S33 | ELM|EPSD|PSP | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | AMEPDRKAAVsHWQQQsyLDsGIHsGATtTAPsLsGKGNPE |
| P35222 | S37 | ELM|EPSD|PSP | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | DRKAAVsHWQQQsyLDsGIHsGATtTAPsLsGKGNPEEEDV |
| P35222 | T41 | ELM|EPSD|PSP | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | AVsHWQQQsyLDsGIHsGATtTAPsLsGKGNPEEEDVDTsQ |
| P35579 | S1713 | Sugiyama | MYH9 | ERAKRQAQQERDELADEIANssGKGALALEEKRRLEARIAQ |
| P35579 | S1714 | Sugiyama | MYH9 | RAKRQAQQERDELADEIANssGKGALALEEKRRLEARIAQL |
| P38936 | T57 | PSP | CDKN1A CAP20 CDKN1 CIP1 MDA6 PIC1 SDI1 WAF1 | LMAGCIQEARERWNFDFVtEtPLEGDFAWERVRGLGLPKLy |
| P40763 | S727 | PSP | STAT3 APRF | KTKFICVtPttCsNtIDLPMsPRTLDSLMQFGNNGEGAEPS |
| P40763 | T714 | PSP | STAT3 APRF | HPEADPGsAAPyLKTKFICVtPttCsNtIDLPMsPRTLDSL |
| P41091 | T109 | Sugiyama | EIF2S3 EIF2G | YKLDDPSCPRPECyRSCGsstPDEFPtDIPGtKGNFKLVRH |
| P49840 | S278 | iPTMNet|EPSD | GSK3A | VLKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYT |
| P49840 | S282 | Sugiyama | GSK3A | CDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTSSID |
| P49840 | Y279 | SIGNOR|iPTMNet|EPSD|PSP|Sugiyama | GSK3A | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P49841 | S219 | Sugiyama | GSK3B | CDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTSSID |
| P49841 | Y216 | Sugiyama | GSK3B | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P52565 | T160 | Sugiyama | ARHGDIA GDIA1 | DKtDyMVGsYGPRAEEyEFLtPVEEAPKGMLARGsYsIKSR |
| P52565 | Y156 | Sugiyama | ARHGDIA GDIA1 | GVKIDKtDyMVGsYGPRAEEyEFLtPVEEAPKGMLARGsYs |
| P52630 | S381 | SIGNOR|PSP | STAT2 | VSIDRNPPQLQGFRKFNILTsNQKtLtPEKGQsQGLIWDFG |
| P52630 | S393 | SIGNOR|PSP | STAT2 | FRKFNILTsNQKtLtPEKGQsQGLIWDFGYLtLVEQRSGGS |
| P52630 | T385 | SIGNOR|PSP | STAT2 | RNPPQLQGFRKFNILTsNQKtLtPEKGQsQGLIWDFGYLtL |
| P53396 | S451 | ELM | ACLY | AAHTANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAK |
| P53396 | T447 | ELM | ACLY | QPPTAAHTANFLLNAsGststPAPsRtAsFsEsRADEVAPA |
| P54652 | T38 | Sugiyama | HSPA2 | CVGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKN |
| P55809 | S509 | Sugiyama | OXCT1 OXCT SCOT | LWEGLTVDDVQKSTGCDFAVsPKLMPMQQIAN_________ |
| P61981 | S38 | Sugiyama | YWHAG | ERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKNVVGARRS |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62942 | S9 | Sugiyama | FKBP1A FKBP1 FKBP12 | ____________MGVQVEtIsPGDGRtFPKRGQtCVVHytG |
| P63104 | S28 | Sugiyama | YWHAZ | QKAKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAy |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| Q00613 | S303 | GPS6|ELM|iPTMNet|EPSD | HSF1 HSTF1 | SIDERPLSSsPLVRVKEEPPsPPQsPRVEEAsPGRPssVDt |
| Q04206 | T254 | SIGNOR | RELA NFKB3 | EARGsFSQADVHRQVAIVFRtPPYADPsLQAPVRVsMQLRR |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q07817 | S62 | EPSD|PSP | BCL2L1 BCL2L BCLX | ESEMEtPsAINGNPSWHLADsPAVNGATGHSSSLDAREVIP |
| Q07820 | S159 | SIGNOR|iPTMNet|EPSD | MCL1 BCL2L3 | AVLPLLELVGEsGNNtstDGsLPstPPPAEEEEDELYRQSL |
| Q07820 | T163 | iPTMNet|EPSD | MCL1 BCL2L3 | LLELVGEsGNNtstDGsLPstPPPAEEEEDELYRQSLEIIS |
| Q07869 | S280 | SIGNOR|PSP | PPARA NR1C1 PPAR | ANGIQNKEAEVRIFHCCQCTsVETVTELTEFAKAIPGFANL |
| Q12931 | S568 | Sugiyama | TRAP1 HSP75 HSPC5 | ISVETDIVVDHYKEEKFEDRsPAAECLSEKETEELMAWMRN |
| Q13131 | T490 | PSP | PRKAA1 AMPK1 | YLLDFRsIDDEItEAKsGtAtPQRsGsVsNYRSCQRsDsDA |
| Q13144 | S535 | ELM | EIF2B5 EIF2BE | WGLKINMEEEsEsESEQSMDsEEPDsRGGsPQMDDIKVFQN |
| Q13144 | S540 | SIGNOR|iPTMNet|EPSD | EIF2B5 EIF2BE | NMEEEsEsESEQSMDsEEPDsRGGsPQMDDIKVFQNEVLGT |
| Q13144 | S544 | iPTMNet|EPSD | EIF2B5 EIF2BE | EsEsESEQSMDsEEPDsRGGsPQMDDIKVFQNEVLGTLQRG |
| Q13283 | S231 | Sugiyama | G3BP1 G3BP | QEEKPEPVLEETAPEDAQKsssPAPADIAQtVQEDLRtFsW |
| Q13563 | S76 | SIGNOR|EPSD|PSP | PKD2 TRPP1 TRPP2 | MQRIRQAAARDPPAGAAAsPsPPLsSCSRQAWSRDNPGFEA |
| Q13610 | S57 | Sugiyama | PWP1 | AEAKEKLQEEGGGsDEEEtGsPsEDGMQsARTQARPREPLE |
| Q14449 | S358 | SIGNOR|PSP | GRB14 | RLLKYGMQLYQNYMHPYQGRsGCSsQSIsPMRsIsENSLVA |
| Q14449 | S362 | SIGNOR|PSP | GRB14 | YGMQLYQNYMHPYQGRsGCSsQSIsPMRsIsENSLVAMDFS |
| Q14449 | S366 | SIGNOR|PSP | GRB14 | LYQNYMHPYQGRsGCSsQSIsPMRsIsENSLVAMDFSGQKS |
| Q14449 | S419 | PSP | GRB14 | AVEEGLAWRKKGCLRLGTHGsPtAsSQSSATNMAIHRSQPW |
| Q14449 | S423 | PSP | GRB14 | GLAWRKKGCLRLGTHGsPtAsSQSSATNMAIHRSQPWFHHK |
| Q14596 | T586 | SIGNOR|PSP | NBR1 1A13B KIAA0049 M17S2 MIG19 | LDINIVQELERVPHNtPVDVtPCMsPLPHDsPLIEKPGLGQ |
| Q14653 | S123 | PSP | IRF3 | PHKIYEFVNSGVGDFSQPDTsPDTNGGGSTSDtQEDILDEL |
| Q14653 | S173 | PSP | IRF3 | PDPGPPSLAVAPEPCPQPLRsPsLDNPtPFPNLGPsENPLK |
| Q14653 | T180 | PSP | IRF3 | LAVAPEPCPQPLRsPsLDNPtPFPNLGPsENPLKRLLVPGE |
| Q14980 | S861 | Sugiyama | NUMA1 NMP22 NUMA | ECEKARQELQEAKEKVAGIEsHsELQISRQQNELAELHANL |
| Q15293 | T76 | Sugiyama | RCN1 RCN | FQYDHEAFLGKEDsKtFDQLtPDEsKERLGKIVDRIDNDGD |
| Q15642 | S298 | Sugiyama | TRIP10 CIP4 STOT STP | RPGDVEFEDFsQPMNRAPsDssLGtPsDGRPELRGPGRSRT |
| Q15642 | S299 | Sugiyama | TRIP10 CIP4 STOT STP | PGDVEFEDFsQPMNRAPsDssLGtPsDGRPELRGPGRSRTK |
| Q15642 | S304 | Sugiyama | TRIP10 CIP4 STOT STP | FEDFsQPMNRAPsDssLGtPsDGRPELRGPGRSRTKRWPFG |
| Q15746 | S16 | ELM | MYLK MLCK MLCK1 MYLK1 | _____MGDVKLVASSHIsKTsLsVDPSRVDSMPLTEAPAFI |
| Q16555 | S518 | EPSD|PSP | DPYSL2 CRMP2 ULIP2 | LyDGPVCEVsVtPKtVtPAssAKtsPAKQQAPPVRNLHQsG |
| Q16584 | S789 | EPSD | MAP3K11 MLK3 PTK1 SPRK | PsPLRSRIDPWsFVSAGPRPsPLPsPQPAPRRAPWTLFPDS |
| Q16584 | S793 | EPSD | MAP3K11 MLK3 PTK1 SPRK | RSRIDPWsFVSAGPRPsPLPsPQPAPRRAPWTLFPDSDPFW |
| Q2M1Z3 | T789 | SIGNOR | ARHGAP31 CDGAP KIAA1204 | VEVGGPGNLsPPLPPAPPPPtPLEESTPVLLSKGGPEREDS |
| Q5T4S7 | S178 | Sugiyama | UBR4 KIAA0462 KIAA1307 RBAF600 | AKLPQTVKTLSDVEDQKELAsPVsPELRQKEVQMNFLNQLT |
| Q6R327 | T1695 | SIGNOR|EPSD|PSP | RICTOR KIAA1999 | ELFQDVQFLQMHEEAEAVLAtPPKQPIVDTSAEs_______ |
| Q8NHW3 | S49 | SIGNOR|PSP | MAFA | FEVKKEPPEAERFCHRLPPGsLSStPLStPCSsVPSsPSFC |
| Q8NHW3 | S61 | SIGNOR|PSP | MAFA | FCHRLPPGsLSStPLStPCSsVPSsPSFCAPSPGTGGGGGA |
| Q8NHW3 | T53 | SIGNOR|PSP | MAFA | KEPPEAERFCHRLPPGsLSStPLStPCSsVPSsPSFCAPSP |
| Q8NHW3 | T57 | SIGNOR|PSP | MAFA | EAERFCHRLPPGsLSStPLStPCSsVPSsPSFCAPSPGTGG |
| Q8WXI9 | S122 | Sugiyama | GATAD2B KIAA1150 | DEPVDMSARRsEPERGRLtPsPDIIVLsDNEAssPRsSsRM |
| Q8WXI9 | S135 | Sugiyama | GATAD2B KIAA1150 | ERGRLtPsPDIIVLsDNEAssPRsSsRMEERLKAANLEMFK |
| Q92597 | S342 | EPSD|PSP | NDRG1 CAP43 DRG1 RTP | RLMRsRtAsGssVtsLDGtRsRsHtSEGTRsRsHtsEGtRs |
| Q92597 | S352 | EPSD|PSP | NDRG1 CAP43 DRG1 RTP | ssVtsLDGtRsRsHtSEGTRsRsHtsEGtRsRsHtsEGAHL |
| Q92597 | S362 | PSP | NDRG1 CAP43 DRG1 RTP | sRsHtSEGTRsRsHtsEGtRsRsHtsEGAHLDItPNsGAAG |
| Q92908 | S37 | SIGNOR | GATA6 | AGADASDSRAFPAREPSTPPsPISSSSSSCSRGGERGPGGA |
| Q969R2 | S762 | PSP | OSBP2 KIAA1664 ORP4 OSBPL4 | AHYVLSGSWDEQMECSKVMHssPssPsSDGKQKTVYQTLSA |
| Q969R2 | S763 | PSP | OSBP2 KIAA1664 ORP4 OSBPL4 | HYVLSGSWDEQMECSKVMHssPssPsSDGKQKTVYQTLSAK |
| Q969R2 | S766 | PSP | OSBP2 KIAA1664 ORP4 OSBPL4 | LSGSWDEQMECSKVMHssPssPsSDGKQKTVYQTLSAKLLW |
| Q969R2 | S768 | PSP | OSBP2 KIAA1664 ORP4 OSBPL4 | GSWDEQMECSKVMHssPssPsSDGKQKTVYQTLSAKLLWKK |
| Q96C19 | S74 | Sugiyama | EFHD2 SWS1 | ELSAKLLRRADLNQGIGEPQsPsRRVFNPytEFKEFSRKQI |
| Q96F46 | T780 | SIGNOR|EPSD|PSP | IL17RA IL17R | LSCQAQGGCSRPAMVLTDPHtPYEEEQRQSVQsDQGyIsRs |
| Q96IG2 | S139 | PSP | FBXL20 FBL2 | IEVLNLNGCTKTTDATCTSLsKFCsKLRHLDLASCTSITNM |
| Q96IG2 | S143 | PSP | FBXL20 FBL2 | NLNGCTKTTDATCTSLsKFCsKLRHLDLASCTSITNMSLKA |
| Q96IG2 | S251 | PSP | FBXL20 FBL2 | CLQITDEGLITICRGCHKLQsLCAsGCSNITDAILNALGQN |
| Q96IG2 | S255 | PSP | FBXL20 FBL2 | TDEGLITICRGCHKLQsLCAsGCSNITDAILNALGQNCPRL |
| Q96IG2 | S421 | PSP | FBXL20 FBL2 | RTHLPNIKVHAyFAPVtPPPsVGGsRQRFCRCCIIL_____ |
| Q96IG2 | S425 | PSP | FBXL20 FBL2 | PNIKVHAyFAPVtPPPsVGGsRQRFCRCCIIL_________ |
| Q96IG2 | T417 | PSP | FBXL20 FBL2 | IKRLRTHLPNIKVHAyFAPVtPPPsVGGsRQRFCRCCIIL_ |
| Q96K76 | S910 | Sugiyama | USP47 | DGDNGDssKstEtsDFENIEsPLNERDsSAsVDNRELEQHI |
| Q96RR4 | S129 | SIGNOR | CAMKK2 CAMKKB KIAA0787 | LAAGGsLDMNGRCICPsLPysPVssPQssPRLPRRPTVESH |
| Q96RR4 | S133 | SIGNOR | CAMKK2 CAMKKB KIAA0787 | GsLDMNGRCICPsLPysPVssPQssPRLPRRPTVESHHVSI |
| Q96RR4 | S137 | SIGNOR | CAMKK2 CAMKKB KIAA0787 | MNGRCICPsLPysPVssPQssPRLPRRPTVESHHVSITGMQ |
| Q9BYG3 | S230 | GPS6|ELM|EPSD|PSP | NIFK MKI67IP NOPP34 | LRKKKKKVsGtLDtPEKtVDsQGPtPVCtPtFLERRKsQVA |
| Q9BYG3 | T234 | GPS6|SIGNOR|ELM|EPSD|PSP | NIFK MKI67IP NOPP34 | KKKVsGtLDtPEKtVDsQGPtPVCtPtFLERRKsQVAELND |
| Q9NY33 | S242 | Sugiyama | DPP3 | SEPsLDsEVTSKLKSYEFRGsPFQVTRGDyAPILQKVVEQL |
| Q9NZ72 | S60 | SIGNOR|EPSD|PSP | STMN3 SCLIP | MEVKQLDKRAsGQsFEVILKsPSDLsPEsPMLssPPKKKDt |
| Q9NZN8 | S242 | Sugiyama | CNOT2 CDC36 NOT2 HSPC131 MSTP046 | VTGLDLSDFPALADRNRREGsGNPtPLINPLAGRAPYVGMV |
| Q9NZN8 | T246 | Sugiyama | CNOT2 CDC36 NOT2 HSPC131 MSTP046 | DLSDFPALADRNRREGsGNPtPLINPLAGRAPYVGMVTKPA |
| Q9NZQ7 | S279 | SIGNOR|PSP | CD274 B7H1 PDCD1L1 PDCD1LG1 PDL1 | FRLRKGRMMDVKKCGIQDtNsKKQsDtHLEEt_________ |
| Q9NZQ7 | S283 | PSP | CD274 B7H1 PDCD1L1 PDCD1LG1 PDL1 | KGRMMDVKKCGIQDtNsKKQsDtHLEEt_____________ |
| Q9UHI6 | T705 | Sugiyama | DDX20 DP103 GEMIN3 | sEstPVDDRIsLEQPPNGsDtPNPEKyQEsPGIQMKTRLKE |
| Q9UKT9 | S378 | PSP | IKZF3 ZNFN1A3 | ELEKKSIHLPEKSVPSERGLsPNNsGHDstDtDsNHEERQN |
| Q9Y2B0 | S65 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEI |
| Q9Y4H4 | S35 | SIGNOR|PSP | GPSM3 AGS4 C6orf9 G18 | GPPQDEEGWPPPNSTTRPWRsAPPsPPPPGTRHTALGPRsA |
| Q9Y6Q9 | S505 | PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | RNRGSPKIASHQFSPVAGVHsPMAsSGNTGNHSFSSSSLSA |
| Q9Y6Q9 | S509 | SIGNOR|PSP | NCOA3 AIB1 BHLHE42 RAC3 TRAM1 | SPKIASHQFSPVAGVHsPMAsSGNTGNHSFSSSSLSALQAI |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.059559e-09 | 8.975 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 9.106929e-10 | 9.041 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.336205e-09 | 8.874 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.149253e-08 | 7.940 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 3.070747e-07 | 6.513 | 1 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.475939e-06 | 5.459 | 0 | 0 |
| M Phase | R-HSA-68886 | 5.011639e-06 | 5.300 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 5.115657e-06 | 5.291 | 1 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.984938e-05 | 4.525 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.434550e-05 | 4.353 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.824212e-05 | 4.317 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 6.402870e-05 | 4.194 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.313040e-05 | 4.200 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 7.161101e-05 | 4.145 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 7.494524e-05 | 4.125 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 8.540792e-05 | 4.069 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.023650e-04 | 3.990 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.058791e-04 | 3.975 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.037320e-04 | 3.984 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.328570e-04 | 3.877 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.266462e-04 | 3.897 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.266462e-04 | 3.897 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.230398e-04 | 3.910 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.611530e-04 | 3.793 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.651510e-04 | 3.782 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.703300e-04 | 3.769 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.822685e-04 | 3.739 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.165175e-04 | 3.665 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.510081e-04 | 3.600 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.555959e-04 | 3.592 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 2.736315e-04 | 3.563 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.840336e-04 | 3.547 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.038836e-04 | 3.517 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.365445e-04 | 3.473 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.554806e-04 | 3.449 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.972612e-04 | 3.401 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.972612e-04 | 3.401 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.866113e-04 | 3.413 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 4.346509e-04 | 3.362 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 4.543587e-04 | 3.343 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.805323e-04 | 3.318 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.015445e-04 | 3.300 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 4.982374e-04 | 3.303 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 6.297978e-04 | 3.201 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 6.589384e-04 | 3.181 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 6.589384e-04 | 3.181 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 7.240554e-04 | 3.140 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 7.240554e-04 | 3.140 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 8.252863e-04 | 3.083 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 8.252863e-04 | 3.083 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 8.252863e-04 | 3.083 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 7.691229e-04 | 3.114 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 7.963787e-04 | 3.099 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 7.963787e-04 | 3.099 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 7.963787e-04 | 3.099 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 7.963787e-04 | 3.099 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 8.369321e-04 | 3.077 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.386730e-04 | 3.076 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 9.034232e-04 | 3.044 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 8.817949e-04 | 3.055 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 9.194217e-04 | 3.036 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 9.568040e-04 | 3.019 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.033388e-03 | 2.986 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.189289e-03 | 2.925 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.316121e-03 | 2.881 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.313226e-03 | 2.882 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.376385e-03 | 2.861 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.712796e-03 | 2.766 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.631531e-03 | 2.787 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.775095e-03 | 2.751 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.032080e-03 | 2.692 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.032080e-03 | 2.692 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.032080e-03 | 2.692 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.025974e-03 | 2.693 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.921010e-03 | 2.716 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.018604e-03 | 2.695 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.985291e-03 | 2.702 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.980806e-03 | 2.703 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.063554e-03 | 2.685 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.463185e-03 | 2.609 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.463517e-03 | 2.608 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 2.477373e-03 | 2.606 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.559002e-03 | 2.592 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.688810e-03 | 2.570 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 2.970896e-03 | 2.527 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.014227e-03 | 2.521 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.137668e-03 | 2.503 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.137668e-03 | 2.503 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.264733e-03 | 2.486 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.422673e-03 | 2.466 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.485451e-03 | 2.458 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 3.475435e-03 | 2.459 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.523732e-03 | 2.453 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.705682e-03 | 2.431 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.167812e-03 | 2.380 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.986851e-03 | 2.399 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 3.986851e-03 | 2.399 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.179867e-03 | 2.379 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.272020e-03 | 2.369 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 4.285891e-03 | 2.368 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 4.287303e-03 | 2.368 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 4.478010e-03 | 2.349 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 5.046047e-03 | 2.297 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.788513e-03 | 2.320 | 1 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.833926e-03 | 2.316 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.932300e-03 | 2.307 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 5.071382e-03 | 2.295 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 5.211465e-03 | 2.283 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.211465e-03 | 2.283 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.227258e-03 | 2.282 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 6.326176e-03 | 2.199 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 6.480051e-03 | 2.188 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 6.926575e-03 | 2.159 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 6.926575e-03 | 2.159 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 6.926575e-03 | 2.159 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 7.010026e-03 | 2.154 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 7.010026e-03 | 2.154 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 7.139569e-03 | 2.146 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 7.400657e-03 | 2.131 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 7.599996e-03 | 2.119 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 7.663869e-03 | 2.116 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.697047e-03 | 2.114 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 7.824305e-03 | 2.107 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 8.546784e-03 | 2.068 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 9.031329e-03 | 2.044 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 8.948661e-03 | 2.048 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 9.256572e-03 | 2.034 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 9.269575e-03 | 2.033 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 9.756599e-03 | 2.011 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 9.901892e-03 | 2.004 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.073671e-02 | 1.969 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.025963e-02 | 1.989 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 9.890575e-03 | 2.005 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.135176e-02 | 1.945 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.197907e-02 | 1.922 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.279447e-02 | 1.893 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 1.312977e-02 | 1.882 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.312977e-02 | 1.882 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 1.321847e-02 | 1.879 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.354933e-02 | 1.868 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.367673e-02 | 1.864 | 1 | 1 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.401051e-02 | 1.854 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.439474e-02 | 1.842 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.451706e-02 | 1.838 | 1 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 1.519843e-02 | 1.818 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.567062e-02 | 1.805 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.626922e-02 | 1.789 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.625260e-02 | 1.789 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.626922e-02 | 1.789 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.652592e-02 | 1.782 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.663196e-02 | 1.779 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.669731e-02 | 1.777 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.686244e-02 | 1.773 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.686244e-02 | 1.773 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.692264e-02 | 1.772 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.719411e-02 | 1.765 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.719411e-02 | 1.765 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.723509e-02 | 1.764 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.810370e-02 | 1.742 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.982232e-02 | 1.703 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.982232e-02 | 1.703 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.859174e-02 | 1.731 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.931034e-02 | 1.714 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.864476e-02 | 1.729 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.892350e-02 | 1.723 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.925738e-02 | 1.715 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.990259e-02 | 1.701 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.871965e-02 | 1.728 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.834222e-02 | 1.737 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.008365e-02 | 1.697 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 2.008365e-02 | 1.697 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 2.008365e-02 | 1.697 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 2.029857e-02 | 1.693 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.029857e-02 | 1.693 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.030138e-02 | 1.692 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.030138e-02 | 1.692 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.060038e-02 | 1.686 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.110452e-02 | 1.676 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.296464e-02 | 1.639 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.296464e-02 | 1.639 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.306389e-02 | 1.637 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.306389e-02 | 1.637 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.306389e-02 | 1.637 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 2.346500e-02 | 1.630 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.365524e-02 | 1.626 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.707237e-02 | 1.567 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.468578e-02 | 1.608 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.600271e-02 | 1.585 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.707237e-02 | 1.567 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.585093e-02 | 1.588 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.580685e-02 | 1.588 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.707237e-02 | 1.567 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 2.411719e-02 | 1.618 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 2.468578e-02 | 1.608 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.532142e-02 | 1.597 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.736435e-02 | 1.563 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.754106e-02 | 1.560 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.754106e-02 | 1.560 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.754106e-02 | 1.560 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.754106e-02 | 1.560 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.754106e-02 | 1.560 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 2.948063e-02 | 1.530 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.948063e-02 | 1.530 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.091502e-02 | 1.510 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.099916e-02 | 1.509 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 3.134836e-02 | 1.504 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.164293e-02 | 1.500 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.178372e-02 | 1.498 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.209803e-02 | 1.494 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.569072e-02 | 1.447 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.479941e-02 | 1.458 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 3.487459e-02 | 1.457 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.673590e-02 | 1.435 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.829320e-02 | 1.417 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 3.694481e-02 | 1.432 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.561786e-02 | 1.448 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.744699e-02 | 1.427 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.913191e-02 | 1.407 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.913191e-02 | 1.407 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.150952e-02 | 1.382 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.199090e-02 | 1.377 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 4.263733e-02 | 1.370 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.263733e-02 | 1.370 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.263733e-02 | 1.370 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.323861e-02 | 1.364 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 4.399994e-02 | 1.357 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.470305e-02 | 1.350 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.470305e-02 | 1.350 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.470305e-02 | 1.350 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 4.524366e-02 | 1.344 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.550459e-02 | 1.342 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.550459e-02 | 1.342 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 4.558814e-02 | 1.341 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 4.691215e-02 | 1.329 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.722055e-02 | 1.326 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.850440e-02 | 1.314 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.850485e-02 | 1.314 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 5.704668e-02 | 1.244 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 5.704668e-02 | 1.244 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 5.704668e-02 | 1.244 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 5.416758e-02 | 1.266 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 5.651030e-02 | 1.248 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.651030e-02 | 1.248 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.511648e-02 | 1.259 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 5.621713e-02 | 1.250 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.064495e-02 | 1.295 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 5.416758e-02 | 1.266 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.856015e-02 | 1.232 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.842482e-02 | 1.233 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 5.704668e-02 | 1.244 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.856015e-02 | 1.232 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.856015e-02 | 1.232 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.856015e-02 | 1.232 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.856015e-02 | 1.232 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.742083e-02 | 1.241 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 4.922578e-02 | 1.308 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.543767e-02 | 1.256 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 5.416758e-02 | 1.266 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.856015e-02 | 1.232 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.511648e-02 | 1.259 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 6.008775e-02 | 1.221 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.061951e-02 | 1.217 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.061951e-02 | 1.217 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 6.114312e-02 | 1.214 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 6.114312e-02 | 1.214 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 6.116856e-02 | 1.213 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 6.179187e-02 | 1.209 | 0 | 0 |
| IRS activation | R-HSA-74713 | 6.179187e-02 | 1.209 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 6.179187e-02 | 1.209 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 6.179187e-02 | 1.209 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 6.339635e-02 | 1.198 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.425630e-02 | 1.192 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 6.554310e-02 | 1.183 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 6.651357e-02 | 1.177 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.652403e-02 | 1.177 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.747891e-02 | 1.171 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 6.800987e-02 | 1.167 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 6.924531e-02 | 1.160 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 6.924531e-02 | 1.160 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 6.966967e-02 | 1.157 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 6.966967e-02 | 1.157 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 6.966967e-02 | 1.157 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 8.423846e-02 | 1.074 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.423846e-02 | 1.074 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 8.342993e-02 | 1.079 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 8.342993e-02 | 1.079 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 7.751876e-02 | 1.111 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 7.751876e-02 | 1.111 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 7.105288e-02 | 1.148 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 8.381068e-02 | 1.077 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 8.424170e-02 | 1.074 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 8.080969e-02 | 1.093 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.200327e-02 | 1.143 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 7.216412e-02 | 1.142 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 8.439803e-02 | 1.074 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 7.200327e-02 | 1.143 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.019198e-02 | 1.096 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 7.751876e-02 | 1.111 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 8.719288e-02 | 1.060 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 8.368201e-02 | 1.077 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 8.303073e-02 | 1.081 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 8.525301e-02 | 1.069 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 7.275066e-02 | 1.138 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 8.246296e-02 | 1.084 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.031101e-02 | 1.153 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 7.886372e-02 | 1.103 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.381068e-02 | 1.077 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 7.618851e-02 | 1.118 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.506163e-02 | 1.125 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 7.247708e-02 | 1.140 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 7.247708e-02 | 1.140 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 7.247708e-02 | 1.140 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 7.886372e-02 | 1.103 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 8.967251e-02 | 1.047 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 9.038448e-02 | 1.044 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.317826e-02 | 1.031 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 9.345126e-02 | 1.029 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 9.345126e-02 | 1.029 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 9.345126e-02 | 1.029 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 9.345126e-02 | 1.029 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 9.345126e-02 | 1.029 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 9.345126e-02 | 1.029 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 9.356324e-02 | 1.029 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 9.356324e-02 | 1.029 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 9.356324e-02 | 1.029 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 9.450586e-02 | 1.025 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 9.456206e-02 | 1.024 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 9.478147e-02 | 1.023 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.582750e-02 | 1.019 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 9.685023e-02 | 1.014 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 9.902394e-02 | 1.004 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 9.902394e-02 | 1.004 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 1.012096e-01 | 0.995 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.198668e-01 | 0.921 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.198668e-01 | 0.921 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.198668e-01 | 0.921 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.198668e-01 | 0.921 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.198668e-01 | 0.921 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.198668e-01 | 0.921 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.198668e-01 | 0.921 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.198668e-01 | 0.921 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 1.198668e-01 | 0.921 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.346785e-01 | 0.871 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.346785e-01 | 0.871 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.346785e-01 | 0.871 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.346785e-01 | 0.871 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.278159e-01 | 0.893 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 1.278159e-01 | 0.893 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.278159e-01 | 0.893 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.278159e-01 | 0.893 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.159680e-01 | 0.936 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 1.043334e-01 | 0.982 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 1.341860e-01 | 0.872 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 1.353332e-01 | 0.869 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.338588e-01 | 0.873 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.045262e-01 | 0.981 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.309798e-01 | 0.883 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.228496e-01 | 0.911 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 1.353332e-01 | 0.869 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.295512e-01 | 0.888 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.066233e-01 | 0.972 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 1.195864e-01 | 0.922 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.096173e-01 | 0.960 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.061452e-01 | 0.974 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.338588e-01 | 0.873 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.162046e-01 | 0.935 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.304675e-01 | 0.884 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.244180e-01 | 0.905 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.045262e-01 | 0.981 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.195864e-01 | 0.922 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.146806e-01 | 0.941 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.018767e-01 | 0.992 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.061452e-01 | 0.974 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.045262e-01 | 0.981 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.252780e-01 | 0.902 | 1 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.156191e-01 | 0.937 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.338588e-01 | 0.873 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.091324e-01 | 0.962 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.161889e-01 | 0.935 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.346785e-01 | 0.871 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.278159e-01 | 0.893 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 1.159680e-01 | 0.936 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 1.232717e-01 | 0.909 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.350288e-01 | 0.870 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.309798e-01 | 0.883 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.143759e-01 | 0.942 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 1.346785e-01 | 0.871 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.309798e-01 | 0.883 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.066233e-01 | 0.972 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.087542e-01 | 0.964 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.159680e-01 | 0.936 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.353332e-01 | 0.869 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.227680e-01 | 0.911 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 1.375231e-01 | 0.862 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.375231e-01 | 0.862 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.375231e-01 | 0.862 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.375231e-01 | 0.862 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.375231e-01 | 0.862 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.396483e-01 | 0.855 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.413925e-01 | 0.850 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.413925e-01 | 0.850 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.413925e-01 | 0.850 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 1.426265e-01 | 0.846 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.442182e-01 | 0.841 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.459770e-01 | 0.836 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.463305e-01 | 0.835 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 1.488316e-01 | 0.827 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 1.504630e-01 | 0.823 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 1.506025e-01 | 0.822 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.506025e-01 | 0.822 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.506025e-01 | 0.822 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.506025e-01 | 0.822 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.506025e-01 | 0.822 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.506025e-01 | 0.822 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.506025e-01 | 0.822 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 1.506025e-01 | 0.822 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 1.509293e-01 | 0.821 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.511144e-01 | 0.821 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.515240e-01 | 0.820 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 1.522852e-01 | 0.817 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.535881e-01 | 0.814 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.555758e-01 | 0.808 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.555758e-01 | 0.808 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.586327e-01 | 0.800 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.253717e-01 | 0.647 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.253717e-01 | 0.647 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.253717e-01 | 0.647 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.790505e-01 | 0.747 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.790505e-01 | 0.747 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 1.790505e-01 | 0.747 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.790505e-01 | 0.747 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.252218e-01 | 0.647 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.252218e-01 | 0.647 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.252218e-01 | 0.647 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.252218e-01 | 0.647 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.675315e-01 | 0.776 | 0 | 0 |
| RSK activation | R-HSA-444257 | 1.675315e-01 | 0.776 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.675315e-01 | 0.776 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 1.675315e-01 | 0.776 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.675315e-01 | 0.776 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.992181e-01 | 0.701 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.747983e-01 | 0.757 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.321723e-01 | 0.634 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 2.002084e-01 | 0.699 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.740728e-01 | 0.759 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.740728e-01 | 0.759 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 1.740728e-01 | 0.759 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 2.266330e-01 | 0.645 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 2.266330e-01 | 0.645 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 2.266330e-01 | 0.645 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 1.955302e-01 | 0.709 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.955302e-01 | 0.709 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.647531e-01 | 0.783 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 1.887842e-01 | 0.724 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.178440e-01 | 0.662 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.178440e-01 | 0.662 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.178440e-01 | 0.662 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.178440e-01 | 0.662 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 2.162863e-01 | 0.665 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.714264e-01 | 0.766 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.632826e-01 | 0.787 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.632826e-01 | 0.787 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 1.632826e-01 | 0.787 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 1.668413e-01 | 0.778 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.880923e-01 | 0.726 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.011070e-01 | 0.697 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.807259e-01 | 0.743 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.408120e-01 | 0.618 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.408120e-01 | 0.618 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.823257e-01 | 0.739 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.644683e-01 | 0.784 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 2.282530e-01 | 0.642 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 2.282530e-01 | 0.642 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.276025e-01 | 0.643 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.654922e-01 | 0.781 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.249618e-01 | 0.648 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.249618e-01 | 0.648 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.249618e-01 | 0.648 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.287327e-01 | 0.641 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.740728e-01 | 0.759 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 1.984845e-01 | 0.702 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.162863e-01 | 0.665 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.040968e-01 | 0.690 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.992181e-01 | 0.701 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.346368e-01 | 0.630 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.148877e-01 | 0.668 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.282579e-01 | 0.642 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.162863e-01 | 0.665 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.754778e-01 | 0.756 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.287327e-01 | 0.641 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 1.814862e-01 | 0.741 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 1.611832e-01 | 0.793 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 2.011070e-01 | 0.697 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.252218e-01 | 0.647 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.408939e-01 | 0.618 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.162863e-01 | 0.665 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 1.945313e-01 | 0.711 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.346368e-01 | 0.630 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.640773e-01 | 0.785 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.800185e-01 | 0.745 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 1.923560e-01 | 0.716 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.668413e-01 | 0.778 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.887842e-01 | 0.724 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 1.923560e-01 | 0.716 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.196732e-01 | 0.658 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.242479e-01 | 0.649 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.196732e-01 | 0.658 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.721678e-01 | 0.764 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 2.321723e-01 | 0.634 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.927707e-01 | 0.715 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.701252e-01 | 0.769 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.089946e-01 | 0.680 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.321723e-01 | 0.634 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 1.992181e-01 | 0.701 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.955302e-01 | 0.709 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.219628e-01 | 0.654 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.405161e-01 | 0.619 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 2.051616e-01 | 0.688 | 1 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.736106e-01 | 0.760 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.945313e-01 | 0.711 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 2.029360e-01 | 0.693 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 2.029360e-01 | 0.693 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.039337e-01 | 0.691 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.253717e-01 | 0.647 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.992181e-01 | 0.701 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.945421e-01 | 0.711 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.890525e-01 | 0.723 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.039337e-01 | 0.691 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.408939e-01 | 0.618 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.831266e-01 | 0.737 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.675315e-01 | 0.776 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 1.841263e-01 | 0.735 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.721678e-01 | 0.764 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.642115e-01 | 0.785 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 1.647531e-01 | 0.783 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.283206e-01 | 0.641 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 2.266330e-01 | 0.645 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.812888e-01 | 0.742 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.992181e-01 | 0.701 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 2.419718e-01 | 0.616 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.423388e-01 | 0.616 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.489122e-01 | 0.604 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.511563e-01 | 0.600 | 1 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.529607e-01 | 0.597 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 2.538723e-01 | 0.595 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 2.538723e-01 | 0.595 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.538723e-01 | 0.595 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 2.538723e-01 | 0.595 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.545025e-01 | 0.594 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.545025e-01 | 0.594 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.557896e-01 | 0.592 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 2.557896e-01 | 0.592 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.559386e-01 | 0.592 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 2.559386e-01 | 0.592 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 2.570375e-01 | 0.590 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.570375e-01 | 0.590 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.643161e-01 | 0.578 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.645580e-01 | 0.577 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.645580e-01 | 0.577 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.656384e-01 | 0.576 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 2.660074e-01 | 0.575 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 2.660074e-01 | 0.575 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 2.660074e-01 | 0.575 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 2.660074e-01 | 0.575 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 2.660074e-01 | 0.575 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.182348e-01 | 0.497 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.182348e-01 | 0.497 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 3.182348e-01 | 0.497 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.182348e-01 | 0.497 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.182348e-01 | 0.497 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.182348e-01 | 0.497 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.182348e-01 | 0.497 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 2.721241e-01 | 0.565 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.721241e-01 | 0.565 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.721241e-01 | 0.565 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.721241e-01 | 0.565 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.721241e-01 | 0.565 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.721241e-01 | 0.565 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 3.999701e-01 | 0.398 | 0 | 0 |
| Defective visual phototransduction due to ABCA4 loss of function | R-HSA-9918454 | 3.999701e-01 | 0.398 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.999701e-01 | 0.398 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 3.999701e-01 | 0.398 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 3.999701e-01 | 0.398 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.999701e-01 | 0.398 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.999701e-01 | 0.398 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 3.999701e-01 | 0.398 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 3.999701e-01 | 0.398 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 3.189193e-01 | 0.496 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 3.189193e-01 | 0.496 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.189193e-01 | 0.496 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 3.649595e-01 | 0.438 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 3.649595e-01 | 0.438 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 4.719105e-01 | 0.326 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.719105e-01 | 0.326 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.719105e-01 | 0.326 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.817303e-01 | 0.550 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.349256e-01 | 0.475 | 1 | 1 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.349256e-01 | 0.475 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.100181e-01 | 0.509 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.100181e-01 | 0.509 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.100181e-01 | 0.509 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 4.097533e-01 | 0.387 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 4.097533e-01 | 0.387 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 4.097533e-01 | 0.387 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.097533e-01 | 0.387 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 4.097533e-01 | 0.387 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.700675e-01 | 0.569 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.700675e-01 | 0.569 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.693974e-01 | 0.433 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.385559e-01 | 0.470 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 3.132432e-01 | 0.504 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.916392e-01 | 0.535 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.727435e-01 | 0.564 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 2.727435e-01 | 0.564 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 4.035294e-01 | 0.394 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 4.035294e-01 | 0.394 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 4.035294e-01 | 0.394 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.529381e-01 | 0.344 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 4.529381e-01 | 0.344 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 2.736009e-01 | 0.563 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 2.918228e-01 | 0.535 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 2.918228e-01 | 0.535 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 2.918228e-01 | 0.535 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 2.918228e-01 | 0.535 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 2.727575e-01 | 0.564 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 3.629543e-01 | 0.440 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.957214e-01 | 0.403 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.324859e-01 | 0.478 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 2.697161e-01 | 0.569 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.697161e-01 | 0.569 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 4.371043e-01 | 0.359 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 4.371043e-01 | 0.359 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.371043e-01 | 0.359 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 4.371043e-01 | 0.359 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 2.863496e-01 | 0.543 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 3.288230e-01 | 0.483 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.046477e-01 | 0.516 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.240513e-01 | 0.373 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.240513e-01 | 0.373 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.942560e-01 | 0.306 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 3.373828e-01 | 0.472 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 4.128153e-01 | 0.384 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 4.128153e-01 | 0.384 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 3.665477e-01 | 0.436 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.601166e-01 | 0.444 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 4.699381e-01 | 0.328 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 3.938370e-01 | 0.405 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 3.938370e-01 | 0.405 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.938370e-01 | 0.405 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 4.520371e-01 | 0.345 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.778827e-01 | 0.423 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 4.795650e-01 | 0.319 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 4.795650e-01 | 0.319 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 5.018782e-01 | 0.299 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 4.552119e-01 | 0.342 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.695059e-01 | 0.328 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.615600e-01 | 0.336 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 5.065348e-01 | 0.295 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 5.065348e-01 | 0.295 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.328008e-01 | 0.273 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.099912e-01 | 0.292 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.589340e-01 | 0.445 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 3.804282e-01 | 0.420 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 3.003663e-01 | 0.522 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 2.982710e-01 | 0.525 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.597637e-01 | 0.337 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.135433e-01 | 0.504 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 5.328008e-01 | 0.273 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 5.152117e-01 | 0.288 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.942560e-01 | 0.306 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 4.913061e-01 | 0.309 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 4.343048e-01 | 0.362 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 2.817303e-01 | 0.550 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 3.878514e-01 | 0.411 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.936214e-01 | 0.405 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.649595e-01 | 0.438 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 4.529381e-01 | 0.344 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.529381e-01 | 0.344 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.942560e-01 | 0.306 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.699381e-01 | 0.328 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 5.018782e-01 | 0.299 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 3.385559e-01 | 0.470 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 3.663923e-01 | 0.436 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 4.114696e-01 | 0.386 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 2.727435e-01 | 0.564 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 4.291801e-01 | 0.367 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 4.028521e-01 | 0.395 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 4.097533e-01 | 0.387 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.356966e-01 | 0.474 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 3.804282e-01 | 0.420 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.897307e-01 | 0.538 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.881888e-01 | 0.311 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.737168e-01 | 0.563 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.240513e-01 | 0.373 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.923760e-01 | 0.534 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.528387e-01 | 0.452 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 5.065348e-01 | 0.295 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.624098e-01 | 0.441 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 4.176119e-01 | 0.379 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 4.371043e-01 | 0.359 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.667850e-01 | 0.436 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 5.152117e-01 | 0.288 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 4.435870e-01 | 0.353 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 4.348419e-01 | 0.362 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 3.671755e-01 | 0.435 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.349256e-01 | 0.475 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 3.693974e-01 | 0.433 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.693974e-01 | 0.433 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 4.371043e-01 | 0.359 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.879172e-01 | 0.411 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.680835e-01 | 0.330 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.485878e-01 | 0.458 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.035294e-01 | 0.394 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.918228e-01 | 0.535 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 4.371043e-01 | 0.359 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 5.328008e-01 | 0.273 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.923760e-01 | 0.534 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 3.957214e-01 | 0.403 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 5.099912e-01 | 0.292 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.904635e-01 | 0.537 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.804282e-01 | 0.420 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 3.706610e-01 | 0.431 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.520371e-01 | 0.345 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.714131e-01 | 0.566 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 4.278158e-01 | 0.369 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.182348e-01 | 0.497 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.182348e-01 | 0.497 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.182348e-01 | 0.497 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.182348e-01 | 0.497 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.999701e-01 | 0.398 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.999701e-01 | 0.398 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.999701e-01 | 0.398 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 3.999701e-01 | 0.398 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 3.003663e-01 | 0.522 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 3.385559e-01 | 0.470 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.529381e-01 | 0.344 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 4.942560e-01 | 0.306 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.942560e-01 | 0.306 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.942560e-01 | 0.306 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 4.699381e-01 | 0.328 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 4.699381e-01 | 0.328 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 4.520371e-01 | 0.345 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.065348e-01 | 0.295 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 4.489204e-01 | 0.348 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 4.240513e-01 | 0.373 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 3.601166e-01 | 0.444 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 3.014928e-01 | 0.521 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 3.938370e-01 | 0.405 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 4.438107e-01 | 0.353 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.700675e-01 | 0.569 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 3.740791e-01 | 0.427 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.288230e-01 | 0.483 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.018782e-01 | 0.299 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 4.371043e-01 | 0.359 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 4.135667e-01 | 0.383 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.957214e-01 | 0.403 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.116017e-01 | 0.291 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.721241e-01 | 0.565 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.529381e-01 | 0.344 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.529381e-01 | 0.344 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 4.795650e-01 | 0.319 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 4.970631e-01 | 0.304 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.123111e-01 | 0.505 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 3.100181e-01 | 0.509 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 3.385559e-01 | 0.470 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.677676e-01 | 0.572 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.982710e-01 | 0.525 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 4.293773e-01 | 0.367 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 3.123763e-01 | 0.505 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 3.182348e-01 | 0.497 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.182348e-01 | 0.497 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 3.999701e-01 | 0.398 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 3.999701e-01 | 0.398 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 3.999701e-01 | 0.398 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 3.100181e-01 | 0.509 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 4.035294e-01 | 0.394 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 4.529381e-01 | 0.344 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 4.371043e-01 | 0.359 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.804282e-01 | 0.420 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.180103e-01 | 0.498 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 5.018782e-01 | 0.299 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.128153e-01 | 0.384 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 2.887145e-01 | 0.540 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 5.173420e-01 | 0.286 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 4.095925e-01 | 0.388 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.100181e-01 | 0.509 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.693974e-01 | 0.433 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.035294e-01 | 0.394 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.123111e-01 | 0.505 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 3.649595e-01 | 0.438 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 4.529381e-01 | 0.344 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 4.371043e-01 | 0.359 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.476190e-01 | 0.459 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 4.529381e-01 | 0.344 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.385559e-01 | 0.470 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.021603e-01 | 0.396 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 3.100181e-01 | 0.509 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.529381e-01 | 0.344 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.385559e-01 | 0.470 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.942560e-01 | 0.306 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 3.319221e-01 | 0.479 | 1 | 1 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 4.097533e-01 | 0.387 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.887145e-01 | 0.540 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 4.154302e-01 | 0.382 | 1 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.314103e-01 | 0.365 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.942560e-01 | 0.306 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 5.328602e-01 | 0.273 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 5.335339e-01 | 0.273 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.335339e-01 | 0.273 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.335339e-01 | 0.273 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 5.335339e-01 | 0.273 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.335339e-01 | 0.273 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 5.335339e-01 | 0.273 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.339477e-01 | 0.273 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.346984e-01 | 0.272 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.346984e-01 | 0.272 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 5.346984e-01 | 0.272 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 5.352293e-01 | 0.271 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.352293e-01 | 0.271 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 5.352293e-01 | 0.271 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 5.352293e-01 | 0.271 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 5.352293e-01 | 0.271 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 5.352293e-01 | 0.271 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.352293e-01 | 0.271 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.352293e-01 | 0.271 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 5.352293e-01 | 0.271 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 5.352293e-01 | 0.271 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 5.352293e-01 | 0.271 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 5.352293e-01 | 0.271 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.352293e-01 | 0.271 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 5.352909e-01 | 0.271 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.363215e-01 | 0.271 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.380732e-01 | 0.269 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.414932e-01 | 0.266 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.423277e-01 | 0.266 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.471177e-01 | 0.262 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.532067e-01 | 0.257 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.546950e-01 | 0.256 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.546950e-01 | 0.256 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 5.546950e-01 | 0.256 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 5.584679e-01 | 0.253 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 5.584679e-01 | 0.253 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 5.588940e-01 | 0.253 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 5.605053e-01 | 0.251 | 0 | 0 |
| PKA activation | R-HSA-163615 | 5.626088e-01 | 0.250 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 5.626088e-01 | 0.250 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.626088e-01 | 0.250 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 5.626088e-01 | 0.250 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.683199e-01 | 0.245 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.698115e-01 | 0.244 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.706671e-01 | 0.244 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.706671e-01 | 0.244 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 5.706671e-01 | 0.244 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 5.706671e-01 | 0.244 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 5.706671e-01 | 0.244 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.706671e-01 | 0.244 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.706671e-01 | 0.244 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 5.706671e-01 | 0.244 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.706671e-01 | 0.244 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 5.706671e-01 | 0.244 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.706671e-01 | 0.244 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.707708e-01 | 0.244 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.750053e-01 | 0.240 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 5.750053e-01 | 0.240 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 5.794361e-01 | 0.237 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 5.832970e-01 | 0.234 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 5.832970e-01 | 0.234 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 5.832970e-01 | 0.234 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 5.832970e-01 | 0.234 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.907554e-01 | 0.229 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.909594e-01 | 0.228 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.909594e-01 | 0.228 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.909594e-01 | 0.228 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.909594e-01 | 0.228 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.909594e-01 | 0.228 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.909594e-01 | 0.228 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.909594e-01 | 0.228 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.909594e-01 | 0.228 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.911110e-01 | 0.228 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.911110e-01 | 0.228 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 5.911110e-01 | 0.228 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 5.912286e-01 | 0.228 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 5.912286e-01 | 0.228 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 5.948439e-01 | 0.226 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 5.948439e-01 | 0.226 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.997249e-01 | 0.222 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.997249e-01 | 0.222 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 5.999596e-01 | 0.222 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.056052e-01 | 0.218 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 6.056052e-01 | 0.218 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 6.056052e-01 | 0.218 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 6.056052e-01 | 0.218 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 6.056052e-01 | 0.218 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 6.056052e-01 | 0.218 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 6.056052e-01 | 0.218 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.072983e-01 | 0.217 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 6.072983e-01 | 0.217 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 6.072983e-01 | 0.217 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 6.072983e-01 | 0.217 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 6.072983e-01 | 0.217 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 6.186079e-01 | 0.209 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 6.186079e-01 | 0.209 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.186079e-01 | 0.209 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 6.209435e-01 | 0.207 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 6.209435e-01 | 0.207 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.234382e-01 | 0.205 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.253301e-01 | 0.204 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.275861e-01 | 0.202 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 6.294242e-01 | 0.201 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.304333e-01 | 0.200 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.304333e-01 | 0.200 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 6.304333e-01 | 0.200 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 6.383407e-01 | 0.195 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 6.383407e-01 | 0.195 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 6.383407e-01 | 0.195 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.400098e-01 | 0.194 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.400098e-01 | 0.194 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.400098e-01 | 0.194 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.400098e-01 | 0.194 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.400098e-01 | 0.194 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 6.400098e-01 | 0.194 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.400098e-01 | 0.194 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 6.400098e-01 | 0.194 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.400098e-01 | 0.194 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.400098e-01 | 0.194 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.400098e-01 | 0.194 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.400098e-01 | 0.194 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.400098e-01 | 0.194 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.400098e-01 | 0.194 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.400114e-01 | 0.194 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 6.412575e-01 | 0.193 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.412575e-01 | 0.193 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 6.431513e-01 | 0.192 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 6.447130e-01 | 0.191 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 6.447130e-01 | 0.191 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 6.447130e-01 | 0.191 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 6.447130e-01 | 0.191 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 6.447130e-01 | 0.191 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.512469e-01 | 0.186 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 6.512469e-01 | 0.186 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.526736e-01 | 0.185 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 6.526736e-01 | 0.185 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 6.579269e-01 | 0.182 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 6.644829e-01 | 0.178 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 6.651853e-01 | 0.177 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.688993e-01 | 0.175 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 6.688993e-01 | 0.175 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 6.688993e-01 | 0.175 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 6.688993e-01 | 0.175 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 6.689383e-01 | 0.175 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 6.689383e-01 | 0.175 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 6.689383e-01 | 0.175 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 6.692297e-01 | 0.174 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 6.699072e-01 | 0.174 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.711674e-01 | 0.173 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 6.726747e-01 | 0.172 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 6.729715e-01 | 0.172 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.774107e-01 | 0.169 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.797923e-01 | 0.168 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.798112e-01 | 0.168 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.831808e-01 | 0.165 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 6.831808e-01 | 0.165 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.831808e-01 | 0.165 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.831808e-01 | 0.165 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 6.831808e-01 | 0.165 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.831808e-01 | 0.165 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.831808e-01 | 0.165 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 6.831808e-01 | 0.165 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.831808e-01 | 0.165 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 6.831808e-01 | 0.165 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.831808e-01 | 0.165 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 6.851443e-01 | 0.164 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 6.930449e-01 | 0.159 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 6.973324e-01 | 0.157 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 6.973324e-01 | 0.157 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 6.973324e-01 | 0.157 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.973324e-01 | 0.157 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 6.973324e-01 | 0.157 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 6.973324e-01 | 0.157 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 6.973324e-01 | 0.157 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 6.973324e-01 | 0.157 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.973324e-01 | 0.157 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 6.973324e-01 | 0.157 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.973324e-01 | 0.157 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 6.977810e-01 | 0.156 | 1 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 6.979850e-01 | 0.156 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.979850e-01 | 0.156 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 6.979850e-01 | 0.156 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.025690e-01 | 0.153 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 7.031919e-01 | 0.153 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 7.061419e-01 | 0.151 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 7.061419e-01 | 0.151 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 7.076137e-01 | 0.150 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 7.128540e-01 | 0.147 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.154512e-01 | 0.145 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 7.154512e-01 | 0.145 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 7.211768e-01 | 0.142 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.211768e-01 | 0.142 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.211768e-01 | 0.142 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 7.211768e-01 | 0.142 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 7.211768e-01 | 0.142 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 7.211768e-01 | 0.142 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 7.211768e-01 | 0.142 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 7.211768e-01 | 0.142 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.211768e-01 | 0.142 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.211768e-01 | 0.142 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 7.211768e-01 | 0.142 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 7.211768e-01 | 0.142 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 7.211768e-01 | 0.142 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 7.211768e-01 | 0.142 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.211768e-01 | 0.142 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 7.211768e-01 | 0.142 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.211768e-01 | 0.142 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.211768e-01 | 0.142 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 7.211768e-01 | 0.142 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.211768e-01 | 0.142 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 7.237102e-01 | 0.140 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.237102e-01 | 0.140 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 7.237102e-01 | 0.140 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 7.237102e-01 | 0.140 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 7.309503e-01 | 0.136 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.324164e-01 | 0.135 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 7.324164e-01 | 0.135 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 7.338139e-01 | 0.134 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 7.362406e-01 | 0.133 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 7.481166e-01 | 0.126 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 7.481166e-01 | 0.126 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.481166e-01 | 0.126 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 7.481166e-01 | 0.126 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.481989e-01 | 0.126 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 7.500425e-01 | 0.125 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 7.500425e-01 | 0.125 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 7.500425e-01 | 0.125 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.500425e-01 | 0.125 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.500425e-01 | 0.125 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.501354e-01 | 0.125 | 0 | 0 |
| Protein folding | R-HSA-391251 | 7.511222e-01 | 0.124 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.546179e-01 | 0.122 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 7.546179e-01 | 0.122 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 7.546179e-01 | 0.122 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 7.546179e-01 | 0.122 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 7.546179e-01 | 0.122 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 7.546179e-01 | 0.122 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.546179e-01 | 0.122 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.546179e-01 | 0.122 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.546179e-01 | 0.122 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.546179e-01 | 0.122 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 7.546179e-01 | 0.122 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 7.546179e-01 | 0.122 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 7.551147e-01 | 0.122 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.559630e-01 | 0.121 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.559630e-01 | 0.121 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.559630e-01 | 0.121 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.626566e-01 | 0.118 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 7.653556e-01 | 0.116 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.667633e-01 | 0.115 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 7.667633e-01 | 0.115 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 7.667633e-01 | 0.115 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 7.706451e-01 | 0.113 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 7.706451e-01 | 0.113 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 7.724602e-01 | 0.112 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 7.724602e-01 | 0.112 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 7.744776e-01 | 0.111 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.744776e-01 | 0.111 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.744776e-01 | 0.111 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 7.744776e-01 | 0.111 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 7.744776e-01 | 0.111 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.759243e-01 | 0.110 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 7.761837e-01 | 0.110 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 7.761837e-01 | 0.110 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 7.761837e-01 | 0.110 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 7.767083e-01 | 0.110 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.783915e-01 | 0.109 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.824281e-01 | 0.107 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 7.825960e-01 | 0.106 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 7.825960e-01 | 0.106 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 7.840499e-01 | 0.106 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.840499e-01 | 0.106 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.840499e-01 | 0.106 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.840499e-01 | 0.106 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.840499e-01 | 0.106 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.840499e-01 | 0.106 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.840499e-01 | 0.106 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.840499e-01 | 0.106 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.840499e-01 | 0.106 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.840499e-01 | 0.106 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.840499e-01 | 0.106 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 7.880582e-01 | 0.103 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.881421e-01 | 0.103 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 7.881421e-01 | 0.103 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.891229e-01 | 0.103 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 7.891229e-01 | 0.103 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.891229e-01 | 0.103 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 7.904172e-01 | 0.102 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 7.913949e-01 | 0.102 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 7.913949e-01 | 0.102 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 7.913949e-01 | 0.102 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 7.913949e-01 | 0.102 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.918231e-01 | 0.101 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.919382e-01 | 0.101 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 7.919382e-01 | 0.101 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.970066e-01 | 0.099 | 1 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 7.975617e-01 | 0.098 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 7.975617e-01 | 0.098 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 7.975617e-01 | 0.098 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 7.975617e-01 | 0.098 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 7.994341e-01 | 0.097 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 7.996921e-01 | 0.097 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 7.999627e-01 | 0.097 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 8.016775e-01 | 0.096 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 8.033379e-01 | 0.095 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 8.033379e-01 | 0.095 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 8.051247e-01 | 0.094 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.080424e-01 | 0.093 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.080424e-01 | 0.093 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.080424e-01 | 0.093 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.099533e-01 | 0.092 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 8.099533e-01 | 0.092 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 8.099533e-01 | 0.092 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.099533e-01 | 0.092 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 8.099533e-01 | 0.092 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.099533e-01 | 0.092 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.099533e-01 | 0.092 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 8.099533e-01 | 0.092 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 8.099533e-01 | 0.092 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.099533e-01 | 0.092 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.099533e-01 | 0.092 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 8.104684e-01 | 0.091 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 8.104684e-01 | 0.091 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 8.104684e-01 | 0.091 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.104684e-01 | 0.091 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 8.104684e-01 | 0.091 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 8.104684e-01 | 0.091 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 8.104684e-01 | 0.091 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 8.104684e-01 | 0.091 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 8.116843e-01 | 0.091 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 8.132733e-01 | 0.090 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 8.176393e-01 | 0.087 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 8.191285e-01 | 0.087 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.214895e-01 | 0.085 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 8.231816e-01 | 0.085 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.249899e-01 | 0.084 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.265632e-01 | 0.083 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 8.278807e-01 | 0.082 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 8.279693e-01 | 0.082 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 8.279693e-01 | 0.082 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 8.279693e-01 | 0.082 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 8.284058e-01 | 0.082 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 8.294994e-01 | 0.081 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 8.327508e-01 | 0.079 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 8.327508e-01 | 0.079 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.327508e-01 | 0.079 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.327508e-01 | 0.079 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.327508e-01 | 0.079 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 8.327508e-01 | 0.079 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 8.327508e-01 | 0.079 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.327508e-01 | 0.079 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.327508e-01 | 0.079 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.327508e-01 | 0.079 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 8.327508e-01 | 0.079 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 8.327508e-01 | 0.079 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 8.327508e-01 | 0.079 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 8.366271e-01 | 0.077 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.372887e-01 | 0.077 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 8.372887e-01 | 0.077 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 8.375068e-01 | 0.077 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.375068e-01 | 0.077 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 8.388358e-01 | 0.076 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 8.407241e-01 | 0.075 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 8.413868e-01 | 0.075 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 8.440003e-01 | 0.074 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 8.440003e-01 | 0.074 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 8.440003e-01 | 0.074 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.492647e-01 | 0.071 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.492647e-01 | 0.071 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.504130e-01 | 0.070 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 8.504130e-01 | 0.070 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.526453e-01 | 0.069 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 8.528148e-01 | 0.069 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 8.528148e-01 | 0.069 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.528148e-01 | 0.069 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 8.528148e-01 | 0.069 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 8.528148e-01 | 0.069 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 8.528148e-01 | 0.069 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 8.586620e-01 | 0.066 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 8.602940e-01 | 0.065 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 8.602940e-01 | 0.065 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 8.626047e-01 | 0.064 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.704728e-01 | 0.060 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.704728e-01 | 0.060 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.704728e-01 | 0.060 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 8.704728e-01 | 0.060 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 8.704728e-01 | 0.060 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.704728e-01 | 0.060 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 8.704728e-01 | 0.060 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 8.704728e-01 | 0.060 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 8.704728e-01 | 0.060 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 8.704728e-01 | 0.060 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 8.704728e-01 | 0.060 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.704728e-01 | 0.060 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 8.704728e-01 | 0.060 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 8.706261e-01 | 0.060 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 8.706261e-01 | 0.060 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 8.707915e-01 | 0.060 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 8.707915e-01 | 0.060 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 8.720523e-01 | 0.059 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.720523e-01 | 0.059 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.720523e-01 | 0.059 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.720720e-01 | 0.059 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 8.728002e-01 | 0.059 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.728002e-01 | 0.059 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.729358e-01 | 0.059 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.775100e-01 | 0.057 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.796842e-01 | 0.056 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 8.802927e-01 | 0.055 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 8.810609e-01 | 0.055 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 8.842652e-01 | 0.053 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 8.842652e-01 | 0.053 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 8.842652e-01 | 0.053 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 8.843900e-01 | 0.053 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 8.860133e-01 | 0.053 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.860133e-01 | 0.053 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.860133e-01 | 0.053 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 8.860133e-01 | 0.053 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.860133e-01 | 0.053 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 8.860133e-01 | 0.053 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.860133e-01 | 0.053 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.860133e-01 | 0.053 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 8.873101e-01 | 0.052 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 8.874210e-01 | 0.052 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 8.890155e-01 | 0.051 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.893254e-01 | 0.051 | 1 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 8.893254e-01 | 0.051 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.940821e-01 | 0.049 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.940821e-01 | 0.049 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.940821e-01 | 0.049 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 8.940821e-01 | 0.049 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 8.940821e-01 | 0.049 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 8.953902e-01 | 0.048 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 8.953902e-01 | 0.048 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 8.959091e-01 | 0.048 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.960494e-01 | 0.048 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 8.960494e-01 | 0.048 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 8.972045e-01 | 0.047 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.973837e-01 | 0.047 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.996901e-01 | 0.046 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 8.996901e-01 | 0.046 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 8.996901e-01 | 0.046 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.996901e-01 | 0.046 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.996901e-01 | 0.046 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.996901e-01 | 0.046 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 8.996901e-01 | 0.046 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 8.996901e-01 | 0.046 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.996901e-01 | 0.046 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.996901e-01 | 0.046 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.027144e-01 | 0.044 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 9.029462e-01 | 0.044 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 9.030377e-01 | 0.044 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 9.038333e-01 | 0.044 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 9.046147e-01 | 0.044 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 9.046147e-01 | 0.044 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 9.046147e-01 | 0.044 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 9.055127e-01 | 0.043 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.055127e-01 | 0.043 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.055127e-01 | 0.043 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.055127e-01 | 0.043 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 9.055127e-01 | 0.043 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.056154e-01 | 0.043 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.056154e-01 | 0.043 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.056154e-01 | 0.043 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.096585e-01 | 0.041 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.117265e-01 | 0.040 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.117265e-01 | 0.040 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 9.117265e-01 | 0.040 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 9.117265e-01 | 0.040 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 9.117265e-01 | 0.040 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 9.117265e-01 | 0.040 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 9.117265e-01 | 0.040 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 9.147129e-01 | 0.039 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 9.147129e-01 | 0.039 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 9.152263e-01 | 0.038 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.166844e-01 | 0.038 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.180903e-01 | 0.037 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.189232e-01 | 0.037 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.211769e-01 | 0.036 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 9.217544e-01 | 0.035 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.223193e-01 | 0.035 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.223193e-01 | 0.035 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 9.223193e-01 | 0.035 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 9.223193e-01 | 0.035 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.223193e-01 | 0.035 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 9.223193e-01 | 0.035 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 9.223193e-01 | 0.035 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.230665e-01 | 0.035 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.230665e-01 | 0.035 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 9.230665e-01 | 0.035 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.230665e-01 | 0.035 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.259407e-01 | 0.033 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.259407e-01 | 0.033 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 9.260704e-01 | 0.033 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.260704e-01 | 0.033 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.262560e-01 | 0.033 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 9.267280e-01 | 0.033 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.267333e-01 | 0.033 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.306440e-01 | 0.031 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.306440e-01 | 0.031 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 9.306440e-01 | 0.031 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 9.310933e-01 | 0.031 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 9.316415e-01 | 0.031 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 9.316415e-01 | 0.031 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.316415e-01 | 0.031 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.316415e-01 | 0.031 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.316415e-01 | 0.031 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.316415e-01 | 0.031 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.316415e-01 | 0.031 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.323967e-01 | 0.030 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.323967e-01 | 0.030 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.336518e-01 | 0.030 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.337137e-01 | 0.030 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.338235e-01 | 0.030 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.355400e-01 | 0.029 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.360023e-01 | 0.029 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.373931e-01 | 0.028 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.373931e-01 | 0.028 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.375114e-01 | 0.028 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 9.375114e-01 | 0.028 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.375114e-01 | 0.028 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 9.383303e-01 | 0.028 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.383303e-01 | 0.028 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.383303e-01 | 0.028 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.383303e-01 | 0.028 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 9.383303e-01 | 0.028 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.393252e-01 | 0.027 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 9.398454e-01 | 0.027 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.398454e-01 | 0.027 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.398454e-01 | 0.027 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.437299e-01 | 0.025 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 9.437299e-01 | 0.025 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.437299e-01 | 0.025 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.437299e-01 | 0.025 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 9.437788e-01 | 0.025 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.437788e-01 | 0.025 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 9.441467e-01 | 0.025 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.470652e-01 | 0.024 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.470652e-01 | 0.024 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 9.470652e-01 | 0.024 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 9.470652e-01 | 0.024 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.470652e-01 | 0.024 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.470652e-01 | 0.024 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 9.471167e-01 | 0.024 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.471167e-01 | 0.024 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 9.475580e-01 | 0.023 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.487774e-01 | 0.023 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.493564e-01 | 0.023 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.493564e-01 | 0.023 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.515549e-01 | 0.022 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.523508e-01 | 0.021 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.533591e-01 | 0.021 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.533591e-01 | 0.021 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 9.533591e-01 | 0.021 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.534189e-01 | 0.021 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.534189e-01 | 0.021 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.534189e-01 | 0.021 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.534189e-01 | 0.021 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.534189e-01 | 0.021 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.534189e-01 | 0.021 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.564221e-01 | 0.019 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 9.575554e-01 | 0.019 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.575554e-01 | 0.019 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.590102e-01 | 0.018 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.590102e-01 | 0.018 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.590102e-01 | 0.018 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.590102e-01 | 0.018 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 9.590102e-01 | 0.018 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.594254e-01 | 0.018 | 1 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.604885e-01 | 0.018 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.611374e-01 | 0.017 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.613957e-01 | 0.017 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.613957e-01 | 0.017 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.616267e-01 | 0.017 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.616949e-01 | 0.017 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.624600e-01 | 0.017 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.624600e-01 | 0.017 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.624600e-01 | 0.017 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.625356e-01 | 0.017 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 9.625356e-01 | 0.017 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.625474e-01 | 0.017 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 9.631883e-01 | 0.016 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.631883e-01 | 0.016 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.639307e-01 | 0.016 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.639307e-01 | 0.016 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.639307e-01 | 0.016 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.639307e-01 | 0.016 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.639307e-01 | 0.016 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.639307e-01 | 0.016 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.639307e-01 | 0.016 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 9.649074e-01 | 0.016 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.649074e-01 | 0.016 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.649167e-01 | 0.016 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.669320e-01 | 0.015 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.669320e-01 | 0.015 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 9.669320e-01 | 0.015 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 9.669320e-01 | 0.015 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.679605e-01 | 0.014 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.682608e-01 | 0.014 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 9.682608e-01 | 0.014 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.682608e-01 | 0.014 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 9.682608e-01 | 0.014 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.682608e-01 | 0.014 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.682608e-01 | 0.014 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.688080e-01 | 0.014 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.699144e-01 | 0.013 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.703076e-01 | 0.013 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.703076e-01 | 0.013 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 9.704000e-01 | 0.013 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.710464e-01 | 0.013 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.712368e-01 | 0.013 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.720712e-01 | 0.012 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.720712e-01 | 0.012 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.720712e-01 | 0.012 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 9.720712e-01 | 0.012 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 9.720712e-01 | 0.012 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.720712e-01 | 0.012 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.729467e-01 | 0.012 | 1 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 9.733496e-01 | 0.012 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.733496e-01 | 0.012 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.733496e-01 | 0.012 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.733496e-01 | 0.012 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.736895e-01 | 0.012 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.737202e-01 | 0.012 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.745571e-01 | 0.011 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.748055e-01 | 0.011 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.754244e-01 | 0.011 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.754244e-01 | 0.011 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.754244e-01 | 0.011 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.754244e-01 | 0.011 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.754244e-01 | 0.011 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 9.754244e-01 | 0.011 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.759449e-01 | 0.011 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.760894e-01 | 0.011 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.760894e-01 | 0.011 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.760894e-01 | 0.011 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 9.763054e-01 | 0.010 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 9.763054e-01 | 0.010 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 9.767758e-01 | 0.010 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.780175e-01 | 0.010 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.780175e-01 | 0.010 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 9.781784e-01 | 0.010 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.783752e-01 | 0.009 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.783752e-01 | 0.009 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.783752e-01 | 0.009 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 9.783752e-01 | 0.009 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.785557e-01 | 0.009 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 9.787535e-01 | 0.009 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.799407e-01 | 0.009 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.802255e-01 | 0.009 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.804043e-01 | 0.009 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.807746e-01 | 0.008 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.809718e-01 | 0.008 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.809718e-01 | 0.008 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.809718e-01 | 0.008 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.809718e-01 | 0.008 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 9.809718e-01 | 0.008 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.809718e-01 | 0.008 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 9.809718e-01 | 0.008 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 9.809718e-01 | 0.008 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 9.809718e-01 | 0.008 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 9.809718e-01 | 0.008 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.809718e-01 | 0.008 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 9.814130e-01 | 0.008 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 9.818478e-01 | 0.008 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.832568e-01 | 0.007 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.832568e-01 | 0.007 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.845636e-01 | 0.007 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.851174e-01 | 0.007 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.852675e-01 | 0.006 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.852675e-01 | 0.006 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.852675e-01 | 0.006 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.852675e-01 | 0.006 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.852675e-01 | 0.006 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.852675e-01 | 0.006 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.852675e-01 | 0.006 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.852757e-01 | 0.006 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.854458e-01 | 0.006 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.861750e-01 | 0.006 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.866547e-01 | 0.006 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.870368e-01 | 0.006 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 9.870368e-01 | 0.006 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.870368e-01 | 0.006 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.870368e-01 | 0.006 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.876221e-01 | 0.005 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.876221e-01 | 0.005 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.876221e-01 | 0.005 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.876221e-01 | 0.005 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 9.880878e-01 | 0.005 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 9.885938e-01 | 0.005 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.885938e-01 | 0.005 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 9.885938e-01 | 0.005 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.885938e-01 | 0.005 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 9.886952e-01 | 0.005 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.894793e-01 | 0.005 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.896015e-01 | 0.005 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.896015e-01 | 0.005 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.899638e-01 | 0.004 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.899638e-01 | 0.004 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.900868e-01 | 0.004 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.901685e-01 | 0.004 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.902432e-01 | 0.004 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.911693e-01 | 0.004 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.911693e-01 | 0.004 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.912045e-01 | 0.004 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.912065e-01 | 0.004 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.920561e-01 | 0.003 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.920561e-01 | 0.003 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.920699e-01 | 0.003 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.920699e-01 | 0.003 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.922301e-01 | 0.003 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.922301e-01 | 0.003 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.922301e-01 | 0.003 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.925847e-01 | 0.003 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.926486e-01 | 0.003 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 9.931635e-01 | 0.003 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.931635e-01 | 0.003 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 9.931635e-01 | 0.003 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.933984e-01 | 0.003 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.935264e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.936631e-01 | 0.003 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.936631e-01 | 0.003 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.939849e-01 | 0.003 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.940999e-01 | 0.003 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.943375e-01 | 0.002 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 9.945258e-01 | 0.002 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.947076e-01 | 0.002 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 9.947076e-01 | 0.002 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 9.947076e-01 | 0.002 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 9.947076e-01 | 0.002 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.947076e-01 | 0.002 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.947984e-01 | 0.002 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.951974e-01 | 0.002 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.951974e-01 | 0.002 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.953435e-01 | 0.002 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.954819e-01 | 0.002 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.959030e-01 | 0.002 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 9.959030e-01 | 0.002 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.961951e-01 | 0.002 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.963953e-01 | 0.002 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.963953e-01 | 0.002 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.963953e-01 | 0.002 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.963953e-01 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.963953e-01 | 0.002 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 9.963969e-01 | 0.002 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.964729e-01 | 0.002 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.967762e-01 | 0.001 | 0 | 0 |
| Depurination | R-HSA-73927 | 9.968285e-01 | 0.001 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.968285e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.968285e-01 | 0.001 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.969845e-01 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.970070e-01 | 0.001 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.972097e-01 | 0.001 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.972097e-01 | 0.001 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 9.972734e-01 | 0.001 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.974004e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.975168e-01 | 0.001 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 9.975169e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.975450e-01 | 0.001 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.977349e-01 | 0.001 | 1 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.978269e-01 | 0.001 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.979642e-01 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.981848e-01 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.982277e-01 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.982695e-01 | 0.001 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.983365e-01 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.983818e-01 | 0.001 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.984514e-01 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.984868e-01 | 0.001 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 9.985292e-01 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.985576e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.987002e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.987060e-01 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.987060e-01 | 0.001 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.987691e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.987935e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.987935e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.988445e-01 | 0.001 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 9.988616e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.989162e-01 | 0.000 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.989984e-01 | 0.000 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.989984e-01 | 0.000 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.991189e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.991189e-01 | 0.000 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.991907e-01 | 0.000 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.993181e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.993585e-01 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.993867e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.994722e-01 | 0.000 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.994722e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.994917e-01 | 0.000 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.995105e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.995477e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.995477e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.995879e-01 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.995916e-01 | 0.000 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 9.996390e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.996609e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.996815e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.997054e-01 | 0.000 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 9.997067e-01 | 0.000 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 9.997145e-01 | 0.000 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.997183e-01 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.997263e-01 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.997554e-01 | 0.000 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.997560e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.997766e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.998009e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.998009e-01 | 0.000 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.998103e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.998107e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.998107e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.998290e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.998335e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.998418e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.998535e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.998602e-01 | 0.000 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.998602e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.998867e-01 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.999224e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999322e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.999322e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999322e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999389e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.999397e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999513e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999538e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.999594e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.999594e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999683e-01 | 0.000 | 1 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999686e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999724e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.999765e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.999834e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999835e-01 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.999836e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.999899e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999912e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999923e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999929e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.999948e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999976e-01 | 0.000 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.999979e-01 | 0.000 | 1 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999981e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999981e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999981e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999986e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999988e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999989e-01 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.999989e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999991e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999992e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999993e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999994e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999995e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999996e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999998e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999998e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999998e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999999e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999999e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.999999e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000e+00 | 0.000 | 1 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 1 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 1 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | -0.000 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.000000e+00 | 0.000 | 1 | 1 |
| Maturation of nucleoprotein | R-HSA-9683610 | 1.000000e+00 | 0.000 | 1 | 1 |
| Translation of Structural Proteins | R-HSA-9683701 | 1.000000e+00 | 0.000 | 1 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 1.000000e+00 | 0.000 | 1 | 1 |
| Translation of Structural Proteins | R-HSA-9694635 | 1.000000e+00 | 0.000 | 1 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 0.000002 | 5.617 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.000009 | 5.053 | 1 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.000010 | 4.994 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.000012 | 4.933 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.000013 | 4.902 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.000021 | 4.680 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.000022 | 4.663 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.000024 | 4.620 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.000029 | 4.531 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.000035 | 4.457 | 1 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.000038 | 4.416 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.000042 | 4.376 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.000060 | 4.221 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.000092 | 4.036 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.000099 | 4.005 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.000114 | 3.941 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.000122 | 3.913 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.000178 | 3.749 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.000225 | 3.648 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.000221 | 3.656 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.000260 | 3.584 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.000297 | 3.527 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.000332 | 3.479 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.000332 | 3.479 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.000349 | 3.457 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.000355 | 3.450 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.000371 | 3.430 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.000486 | 3.313 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.000486 | 3.313 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.000525 | 3.280 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.000525 | 3.280 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.000466 | 3.331 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.000452 | 3.345 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.000662 | 3.179 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.000653 | 3.185 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.000806 | 3.094 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.000900 | 3.046 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.000918 | 3.037 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.000931 | 3.031 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.000931 | 3.031 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.000987 | 3.006 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.001071 | 2.970 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.001124 | 2.949 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.001272 | 2.896 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.001509 | 2.821 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.001453 | 2.838 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.001434 | 2.844 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.001453 | 2.838 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.001378 | 2.861 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.001509 | 2.821 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.001571 | 2.804 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.001675 | 2.776 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.001675 | 2.776 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.001746 | 2.758 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.001909 | 2.719 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.002087 | 2.681 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.002087 | 2.681 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.002233 | 2.651 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.002155 | 2.667 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.002480 | 2.606 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.002480 | 2.606 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.002792 | 2.554 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.002931 | 2.533 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.002770 | 2.558 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.002792 | 2.554 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.002931 | 2.533 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 0.002792 | 2.554 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 0.002932 | 2.533 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 0.002932 | 2.533 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.002932 | 2.533 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.003278 | 2.484 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.003652 | 2.438 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.003601 | 2.444 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.004452 | 2.351 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.004452 | 2.351 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.005038 | 2.298 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.004950 | 2.305 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.005069 | 2.295 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.005146 | 2.289 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.005297 | 2.276 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.005827 | 2.235 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.006693 | 2.174 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.006526 | 2.185 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.006286 | 2.202 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.006418 | 2.193 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.006489 | 2.188 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.005899 | 2.229 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.006693 | 2.174 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.006286 | 2.202 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.006283 | 2.202 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.006577 | 2.182 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.007149 | 2.146 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.007221 | 2.141 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.007396 | 2.131 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.007976 | 2.098 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.007976 | 2.098 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.007412 | 2.130 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.007960 | 2.099 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.007862 | 2.104 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.009154 | 2.038 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.009254 | 2.034 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.009386 | 2.028 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.009470 | 2.024 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.010710 | 1.970 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.009927 | 2.003 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.010226 | 1.990 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.011718 | 1.931 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.011718 | 1.931 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.011857 | 1.926 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.011857 | 1.926 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.012273 | 1.911 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.012273 | 1.911 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.012592 | 1.900 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.012743 | 1.895 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.013989 | 1.854 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.013749 | 1.862 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.013989 | 1.854 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.014227 | 1.847 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.014407 | 1.841 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.014839 | 1.829 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.014839 | 1.829 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.015011 | 1.824 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.015011 | 1.824 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.015728 | 1.803 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.016327 | 1.787 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.016327 | 1.787 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.016327 | 1.787 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.016327 | 1.787 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.016327 | 1.787 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.017323 | 1.761 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.016716 | 1.777 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.017547 | 1.756 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.017676 | 1.753 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.017972 | 1.745 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.018153 | 1.741 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.018306 | 1.737 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.018565 | 1.731 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.018566 | 1.731 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.020964 | 1.679 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.020964 | 1.679 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.020964 | 1.679 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.020515 | 1.688 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.020515 | 1.688 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.020515 | 1.688 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.019957 | 1.700 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.020515 | 1.688 | 1 | 1 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.021952 | 1.659 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.022142 | 1.655 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.022573 | 1.646 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.022719 | 1.644 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.022719 | 1.644 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.022719 | 1.644 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.022809 | 1.642 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.023351 | 1.632 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.023807 | 1.623 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.025028 | 1.602 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.025549 | 1.593 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.025710 | 1.590 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.025710 | 1.590 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.025729 | 1.590 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.025913 | 1.586 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.028324 | 1.548 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.026519 | 1.576 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.028324 | 1.548 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.029602 | 1.529 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.030007 | 1.523 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.030007 | 1.523 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.030192 | 1.520 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.030496 | 1.516 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.030932 | 1.510 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.031047 | 1.508 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.031047 | 1.508 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.031047 | 1.508 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.031255 | 1.505 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.032656 | 1.486 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.032656 | 1.486 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.033123 | 1.480 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.033633 | 1.473 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.038402 | 1.416 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.036075 | 1.443 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.037663 | 1.424 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.037740 | 1.423 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.038954 | 1.409 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 0.034499 | 1.462 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.038522 | 1.414 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.034445 | 1.463 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.036324 | 1.440 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.036324 | 1.440 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.038402 | 1.416 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.039453 | 1.404 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.042734 | 1.369 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.043150 | 1.365 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.043150 | 1.365 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.043239 | 1.364 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.043239 | 1.364 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.043239 | 1.364 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.045846 | 1.339 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.046145 | 1.336 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.046145 | 1.336 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.046343 | 1.334 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.048931 | 1.310 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.048931 | 1.310 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.049293 | 1.307 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.051679 | 1.287 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.053108 | 1.275 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.054264 | 1.265 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 0.054602 | 1.263 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 0.057627 | 1.239 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.058816 | 1.231 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.056321 | 1.249 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.063748 | 1.196 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.056321 | 1.249 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.058816 | 1.231 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.056933 | 1.245 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.057461 | 1.241 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.060528 | 1.218 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.055607 | 1.255 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.058816 | 1.231 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.058536 | 1.233 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.063863 | 1.195 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.063896 | 1.195 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.064347 | 1.191 | 1 | 1 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.066315 | 1.178 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.073597 | 1.133 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.070809 | 1.150 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.070809 | 1.150 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.070809 | 1.150 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.070809 | 1.150 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.070809 | 1.150 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.070809 | 1.150 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.070809 | 1.150 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.074022 | 1.131 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.074022 | 1.131 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.081675 | 1.088 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.076000 | 1.119 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.076000 | 1.119 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.070809 | 1.150 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.079752 | 1.098 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.074022 | 1.131 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.081675 | 1.088 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.081675 | 1.088 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.073597 | 1.133 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.081675 | 1.088 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.078097 | 1.107 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.080690 | 1.093 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.071153 | 1.148 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.069224 | 1.160 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.069224 | 1.160 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.069224 | 1.160 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.069224 | 1.160 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.075027 | 1.125 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.071888 | 1.143 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.080663 | 1.093 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.069224 | 1.160 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.079492 | 1.100 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.077935 | 1.108 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.069224 | 1.160 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.073597 | 1.133 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.073009 | 1.137 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.073009 | 1.137 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.076346 | 1.117 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.068333 | 1.165 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.083023 | 1.081 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.083897 | 1.076 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.083949 | 1.076 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.083949 | 1.076 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.084306 | 1.074 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 0.084648 | 1.072 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 0.084648 | 1.072 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 0.084648 | 1.072 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.084648 | 1.072 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.084648 | 1.072 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.086422 | 1.063 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.086615 | 1.062 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.086953 | 1.061 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.088276 | 1.054 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 0.091827 | 1.037 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 0.091827 | 1.037 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.091827 | 1.037 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.091501 | 1.039 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 0.111008 | 0.955 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.111008 | 0.955 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.111008 | 0.955 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.098189 | 1.008 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.098189 | 1.008 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.092224 | 1.035 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.105164 | 0.978 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.105444 | 0.977 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.105444 | 0.977 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.096711 | 1.015 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.111008 | 0.955 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.091501 | 1.039 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.095972 | 1.018 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.111008 | 0.955 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.104154 | 0.982 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.090957 | 1.041 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.091802 | 1.037 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.096771 | 1.014 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.098189 | 1.008 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.098189 | 1.008 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.097665 | 1.010 | 1 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.091312 | 1.039 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.094757 | 1.023 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.111008 | 0.955 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.111008 | 0.955 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.091312 | 1.039 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.091777 | 1.037 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.109067 | 0.962 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.099319 | 1.003 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.106683 | 0.972 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.091501 | 1.039 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.111008 | 0.955 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.113468 | 0.945 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.113468 | 0.945 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.113468 | 0.945 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.113738 | 0.944 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.114322 | 0.942 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.114655 | 0.941 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.114655 | 0.941 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 0.114655 | 0.941 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 0.114655 | 0.941 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.114655 | 0.941 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.115179 | 0.939 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.116589 | 0.933 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.120136 | 0.920 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.122374 | 0.912 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.122491 | 0.912 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.125338 | 0.902 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.129233 | 0.889 | 1 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.129721 | 0.887 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.129721 | 0.887 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.130411 | 0.885 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.130833 | 0.883 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.131941 | 0.880 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.132636 | 0.877 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.133924 | 0.873 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.133924 | 0.873 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 0.175227 | 0.756 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 0.250972 | 0.600 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 0.250972 | 0.600 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 0.250972 | 0.600 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.250972 | 0.600 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.250972 | 0.600 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 0.250972 | 0.600 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.250972 | 0.600 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 0.250972 | 0.600 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 0.146871 | 0.833 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 0.146871 | 0.833 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.146871 | 0.833 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 0.146871 | 0.833 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.146871 | 0.833 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.180639 | 0.743 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.180639 | 0.743 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 0.180639 | 0.743 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.319765 | 0.495 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.319765 | 0.495 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 0.319765 | 0.495 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 0.319765 | 0.495 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.319765 | 0.495 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.319765 | 0.495 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.319765 | 0.495 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.319765 | 0.495 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.154118 | 0.812 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.154118 | 0.812 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.154118 | 0.812 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.154118 | 0.812 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.154118 | 0.812 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.250693 | 0.601 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.250693 | 0.601 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.250693 | 0.601 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 0.250693 | 0.601 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.250693 | 0.601 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.250693 | 0.601 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.250693 | 0.601 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 0.382244 | 0.418 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 0.382244 | 0.418 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.382244 | 0.418 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.382244 | 0.418 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 0.382244 | 0.418 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.382244 | 0.418 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.382244 | 0.418 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 0.382244 | 0.418 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.146873 | 0.833 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.201475 | 0.696 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.201475 | 0.696 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.286122 | 0.543 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.286122 | 0.543 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.286122 | 0.543 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.286122 | 0.543 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.226299 | 0.645 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.226299 | 0.645 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.226299 | 0.645 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.166360 | 0.779 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.166360 | 0.779 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.202915 | 0.693 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.251662 | 0.599 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.321367 | 0.493 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.321367 | 0.493 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.321367 | 0.493 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 0.438988 | 0.358 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.438988 | 0.358 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 0.438988 | 0.358 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 0.438988 | 0.358 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.438988 | 0.358 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 0.438988 | 0.358 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.438988 | 0.358 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 0.438988 | 0.358 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.438988 | 0.358 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 0.438988 | 0.358 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.222841 | 0.652 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 0.277407 | 0.557 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.277407 | 0.557 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.277407 | 0.557 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.277407 | 0.557 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.243248 | 0.614 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.356162 | 0.448 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.303385 | 0.518 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.232689 | 0.633 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.165889 | 0.780 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.149452 | 0.825 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.329462 | 0.482 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.390294 | 0.409 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.390294 | 0.409 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.490522 | 0.309 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 0.490522 | 0.309 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.490522 | 0.309 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.490522 | 0.309 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.237197 | 0.625 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.268308 | 0.571 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.306510 | 0.514 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.355514 | 0.449 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.328011 | 0.484 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.423590 | 0.373 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 0.423590 | 0.373 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.423590 | 0.373 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.213983 | 0.670 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.305006 | 0.516 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.267576 | 0.573 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.407101 | 0.390 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.455917 | 0.341 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 0.537325 | 0.270 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.537325 | 0.270 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 0.537325 | 0.270 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.537325 | 0.270 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.537325 | 0.270 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.537325 | 0.270 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.537325 | 0.270 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 0.537325 | 0.270 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.392726 | 0.406 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.392726 | 0.406 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.342789 | 0.465 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 0.487171 | 0.312 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.326401 | 0.486 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.398851 | 0.399 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.373648 | 0.428 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.435405 | 0.361 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.435405 | 0.361 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.247079 | 0.607 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.456436 | 0.341 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.481840 | 0.317 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.481840 | 0.317 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 0.517277 | 0.286 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.314083 | 0.503 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.436173 | 0.360 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.327724 | 0.484 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.452911 | 0.344 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.473144 | 0.325 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.473144 | 0.325 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.450952 | 0.346 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.432426 | 0.364 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.486011 | 0.313 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.518452 | 0.285 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.534371 | 0.272 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.534371 | 0.272 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.433603 | 0.363 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.380030 | 0.420 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.251088 | 0.600 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.206746 | 0.685 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.243604 | 0.613 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.212707 | 0.672 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.207395 | 0.683 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.238826 | 0.622 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.398851 | 0.399 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.374858 | 0.426 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.177826 | 0.750 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.416862 | 0.380 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.165484 | 0.781 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.226299 | 0.645 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.477412 | 0.321 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.301556 | 0.521 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.137888 | 0.860 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.251662 | 0.599 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.222841 | 0.652 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.373648 | 0.428 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.517277 | 0.286 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.505762 | 0.296 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.253079 | 0.597 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.456436 | 0.341 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.321367 | 0.493 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.211160 | 0.675 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.491291 | 0.309 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.517740 | 0.286 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.192707 | 0.715 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.172135 | 0.764 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.250693 | 0.601 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 0.286122 | 0.543 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 0.321367 | 0.493 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.356162 | 0.448 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.356162 | 0.448 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.184781 | 0.733 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.328011 | 0.484 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.423590 | 0.373 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.301556 | 0.521 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.391559 | 0.407 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.505762 | 0.296 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.252908 | 0.597 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.158137 | 0.801 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.371186 | 0.430 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.361191 | 0.442 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.511467 | 0.291 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 0.286122 | 0.543 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.262147 | 0.581 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.278700 | 0.555 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.533041 | 0.273 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.177357 | 0.751 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.321367 | 0.493 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.135026 | 0.870 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.329462 | 0.482 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.381428 | 0.419 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 0.455917 | 0.341 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.168772 | 0.773 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.358190 | 0.446 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.477197 | 0.321 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.502325 | 0.299 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.497644 | 0.303 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.154118 | 0.812 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.285164 | 0.545 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.183554 | 0.736 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.198568 | 0.702 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.441430 | 0.355 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.441430 | 0.355 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.235900 | 0.627 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.215402 | 0.667 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.165889 | 0.780 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.235808 | 0.627 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.180842 | 0.743 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.383440 | 0.416 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.201475 | 0.696 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.183338 | 0.737 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.366425 | 0.436 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.274678 | 0.561 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.274693 | 0.561 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.419346 | 0.377 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.420123 | 0.377 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.180639 | 0.743 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.250693 | 0.601 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.286122 | 0.543 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.137888 | 0.860 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 0.390294 | 0.409 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 0.490522 | 0.309 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.490522 | 0.309 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 0.490522 | 0.309 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.490522 | 0.309 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.381428 | 0.419 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.161383 | 0.792 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.457382 | 0.340 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.497644 | 0.303 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.185166 | 0.732 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.405941 | 0.392 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.197797 | 0.704 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.147817 | 0.830 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.312266 | 0.505 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.312266 | 0.505 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.183554 | 0.736 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.221797 | 0.654 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.366303 | 0.436 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.515333 | 0.288 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.251662 | 0.599 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.250337 | 0.601 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.356162 | 0.448 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.235900 | 0.627 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 0.286122 | 0.543 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.438988 | 0.358 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.198568 | 0.702 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 0.306510 | 0.514 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 0.423590 | 0.373 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.192077 | 0.717 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.368611 | 0.433 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.286548 | 0.543 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.187111 | 0.728 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.173604 | 0.760 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.146871 | 0.833 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.222841 | 0.652 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.136631 | 0.864 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.184781 | 0.733 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.329462 | 0.482 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.423590 | 0.373 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.224431 | 0.649 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.220028 | 0.658 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.188211 | 0.725 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.321367 | 0.493 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.243412 | 0.614 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.166360 | 0.779 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.182200 | 0.739 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.264050 | 0.578 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.445127 | 0.352 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.154752 | 0.810 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.280112 | 0.553 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.507509 | 0.295 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.143861 | 0.842 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.281287 | 0.551 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.505471 | 0.296 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.518452 | 0.285 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.318502 | 0.497 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.136195 | 0.866 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.167171 | 0.777 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.249787 | 0.602 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.190878 | 0.719 | 1 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 0.175227 | 0.756 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 0.250972 | 0.600 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 0.250972 | 0.600 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 0.319765 | 0.495 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.319765 | 0.495 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 0.319765 | 0.495 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.177357 | 0.751 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.177357 | 0.751 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.382244 | 0.418 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.382244 | 0.418 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.146873 | 0.833 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.321367 | 0.493 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.438988 | 0.358 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.277407 | 0.557 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.177826 | 0.750 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.356162 | 0.448 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.303385 | 0.518 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.303385 | 0.518 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.329462 | 0.482 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 0.390294 | 0.409 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.390294 | 0.409 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 0.490522 | 0.309 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.423590 | 0.373 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.381428 | 0.419 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 0.537325 | 0.270 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.285918 | 0.544 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.469532 | 0.328 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.529096 | 0.276 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.235879 | 0.627 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.516262 | 0.287 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.224640 | 0.649 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.237629 | 0.624 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.463310 | 0.334 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.407008 | 0.390 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.393017 | 0.406 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.516262 | 0.287 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.343717 | 0.464 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.449965 | 0.347 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.505762 | 0.296 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.372412 | 0.429 | 1 | 0 |
| Pexophagy | R-HSA-9664873 | 0.356162 | 0.448 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.232689 | 0.633 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.233528 | 0.632 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.285918 | 0.544 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.222841 | 0.652 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.477197 | 0.321 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.511467 | 0.291 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.432909 | 0.364 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.225689 | 0.646 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.183499 | 0.736 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.356162 | 0.448 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.481453 | 0.317 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.280033 | 0.553 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.264050 | 0.578 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.291954 | 0.535 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.153054 | 0.815 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.348574 | 0.458 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.448529 | 0.348 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.291954 | 0.535 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.243604 | 0.613 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.251662 | 0.599 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 0.321367 | 0.493 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.277407 | 0.557 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 0.356162 | 0.448 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.423590 | 0.373 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.455917 | 0.341 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.455917 | 0.341 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.455917 | 0.341 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.505762 | 0.296 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.169787 | 0.770 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.237197 | 0.625 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.379728 | 0.421 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.323332 | 0.490 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.477197 | 0.321 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 0.517277 | 0.286 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.182200 | 0.739 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.243248 | 0.614 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.312266 | 0.505 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.436173 | 0.360 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.487298 | 0.312 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.334367 | 0.476 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.377190 | 0.423 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.377190 | 0.423 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 0.250972 | 0.600 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.146873 | 0.833 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.251662 | 0.599 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.321367 | 0.493 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 0.438988 | 0.358 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 0.438988 | 0.358 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.243248 | 0.614 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 0.490522 | 0.309 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.486011 | 0.313 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.517740 | 0.286 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.517740 | 0.286 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.457796 | 0.339 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.211160 | 0.675 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.407101 | 0.390 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.477197 | 0.321 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.305148 | 0.515 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.349593 | 0.456 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.144207 | 0.841 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.306510 | 0.514 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.360908 | 0.443 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.286137 | 0.543 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.360908 | 0.443 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.360908 | 0.443 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.385534 | 0.414 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.250693 | 0.601 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.390294 | 0.409 | 1 | 1 |
| PECAM1 interactions | R-HSA-210990 | 0.390294 | 0.409 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.224845 | 0.648 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.436271 | 0.360 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.448984 | 0.348 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.505454 | 0.296 | 1 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.498655 | 0.302 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.334888 | 0.475 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.392726 | 0.406 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.461713 | 0.336 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.286901 | 0.542 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.250693 | 0.601 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.164845 | 0.783 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.321367 | 0.493 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.490522 | 0.309 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 0.487171 | 0.312 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.398851 | 0.399 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.454793 | 0.342 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.394930 | 0.403 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.529096 | 0.276 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.183554 | 0.736 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.180842 | 0.743 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.487171 | 0.312 | 1 | 1 |
| Tie2 Signaling | R-HSA-210993 | 0.381428 | 0.419 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.164845 | 0.783 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.253022 | 0.597 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.183554 | 0.736 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.323632 | 0.490 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.362855 | 0.440 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.356162 | 0.448 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.303385 | 0.518 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.517277 | 0.286 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.434537 | 0.362 | 1 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.202798 | 0.693 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.268308 | 0.571 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.306510 | 0.514 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 0.537325 | 0.270 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.211249 | 0.675 | 1 | 1 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.517277 | 0.286 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.272311 | 0.565 | 1 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.537450 | 0.270 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.537450 | 0.270 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.537450 | 0.270 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.537450 | 0.270 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.539105 | 0.268 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.543395 | 0.265 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.546183 | 0.263 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.546183 | 0.263 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 0.546183 | 0.263 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.546183 | 0.263 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.548264 | 0.261 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.548264 | 0.261 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.551747 | 0.258 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.551801 | 0.258 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.551824 | 0.258 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.551824 | 0.258 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.556746 | 0.254 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.556746 | 0.254 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.556746 | 0.254 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.564401 | 0.248 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.565512 | 0.248 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.565512 | 0.248 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.573844 | 0.241 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.573844 | 0.241 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.573854 | 0.241 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.573854 | 0.241 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 0.573854 | 0.241 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.575600 | 0.240 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.579831 | 0.237 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.579831 | 0.237 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.579831 | 0.237 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.579831 | 0.237 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.579831 | 0.237 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.579831 | 0.237 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 0.579831 | 0.237 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 0.579831 | 0.237 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.579831 | 0.237 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.579892 | 0.237 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.580701 | 0.236 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.580701 | 0.236 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.580701 | 0.236 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.580701 | 0.236 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.580714 | 0.236 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.583488 | 0.234 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.589715 | 0.229 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.589715 | 0.229 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.589715 | 0.229 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.591849 | 0.228 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.593990 | 0.226 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.593990 | 0.226 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.595197 | 0.225 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.595197 | 0.225 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.595197 | 0.225 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.595616 | 0.225 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.595616 | 0.225 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.599154 | 0.222 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.600273 | 0.222 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.600273 | 0.222 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 0.600273 | 0.222 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.600273 | 0.222 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.605460 | 0.218 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.606220 | 0.217 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.611808 | 0.213 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.611899 | 0.213 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.611899 | 0.213 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.611899 | 0.213 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.615840 | 0.211 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.615840 | 0.211 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.615840 | 0.211 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.615840 | 0.211 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.616220 | 0.210 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 0.618435 | 0.209 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.618435 | 0.209 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 0.618435 | 0.209 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 0.618435 | 0.209 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.618435 | 0.209 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 0.618435 | 0.209 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.618435 | 0.209 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.618435 | 0.209 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 0.618435 | 0.209 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 0.618435 | 0.209 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.618435 | 0.209 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.618435 | 0.209 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 0.625437 | 0.204 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.625437 | 0.204 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 0.625437 | 0.204 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.625437 | 0.204 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.625437 | 0.204 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.625437 | 0.204 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.625437 | 0.204 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.625437 | 0.204 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.626082 | 0.203 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.626082 | 0.203 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.628477 | 0.202 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.629311 | 0.201 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.635759 | 0.197 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.635759 | 0.197 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.635759 | 0.197 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.635759 | 0.197 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.636699 | 0.196 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.636699 | 0.196 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.637123 | 0.196 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.637123 | 0.196 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.641349 | 0.193 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.646214 | 0.190 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.646214 | 0.190 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 0.646214 | 0.190 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.647490 | 0.189 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.649354 | 0.188 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.649354 | 0.188 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 0.649354 | 0.188 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.649354 | 0.188 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.649354 | 0.188 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.649354 | 0.188 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.652304 | 0.186 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.652304 | 0.186 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.653494 | 0.185 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.653494 | 0.185 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 0.653494 | 0.185 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 0.653494 | 0.185 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 0.653494 | 0.185 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 0.653494 | 0.185 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 0.653494 | 0.185 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 0.653494 | 0.185 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.653494 | 0.185 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.653494 | 0.185 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 0.653494 | 0.185 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 0.653494 | 0.185 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 0.653494 | 0.185 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 0.653494 | 0.185 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.653494 | 0.185 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.653494 | 0.185 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.653494 | 0.185 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 0.653494 | 0.185 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.654946 | 0.184 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.654946 | 0.184 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.654946 | 0.184 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.662599 | 0.179 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.662599 | 0.179 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.662599 | 0.179 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.662599 | 0.179 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.662599 | 0.179 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.667530 | 0.176 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.672040 | 0.173 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.672040 | 0.173 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.672040 | 0.173 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.672040 | 0.173 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.672040 | 0.173 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.672040 | 0.173 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.672040 | 0.173 | 1 | 1 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.673394 | 0.172 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.673394 | 0.172 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.673394 | 0.172 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.676024 | 0.170 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.678460 | 0.168 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.684758 | 0.164 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.684758 | 0.164 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.684758 | 0.164 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.685333 | 0.164 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 0.685333 | 0.164 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 0.685333 | 0.164 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 0.685333 | 0.164 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 0.685333 | 0.164 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.685333 | 0.164 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 0.685333 | 0.164 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.685333 | 0.164 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.686565 | 0.163 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.687966 | 0.162 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.691106 | 0.160 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.693520 | 0.159 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.693520 | 0.159 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.693520 | 0.159 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.693520 | 0.159 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.693520 | 0.159 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.693520 | 0.159 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.693520 | 0.159 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.693520 | 0.159 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.693793 | 0.159 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.693793 | 0.159 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.693793 | 0.159 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.693793 | 0.159 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.693793 | 0.159 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.693793 | 0.159 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.698226 | 0.156 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.698411 | 0.156 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.703840 | 0.153 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.704020 | 0.152 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.706824 | 0.151 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.708596 | 0.150 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.708596 | 0.150 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.713823 | 0.146 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.713823 | 0.146 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.713823 | 0.146 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.713823 | 0.146 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.713823 | 0.146 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.713823 | 0.146 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.713823 | 0.146 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 0.714248 | 0.146 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.714248 | 0.146 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.714248 | 0.146 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 0.714248 | 0.146 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.714248 | 0.146 | 0 | 0 |
| Serotonin receptors | R-HSA-390666 | 0.714248 | 0.146 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 0.714248 | 0.146 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.714248 | 0.146 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.714248 | 0.146 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 0.714248 | 0.146 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.714248 | 0.146 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.720683 | 0.142 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.720683 | 0.142 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.721447 | 0.142 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.722872 | 0.141 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.722872 | 0.141 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.722872 | 0.141 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.723965 | 0.140 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.724336 | 0.140 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.724336 | 0.140 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.724336 | 0.140 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.727761 | 0.138 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.730538 | 0.136 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.732985 | 0.135 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.732985 | 0.135 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.732985 | 0.135 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.735797 | 0.133 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.736621 | 0.133 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.736621 | 0.133 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.738935 | 0.131 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.739872 | 0.131 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.740508 | 0.130 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 0.740508 | 0.130 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 0.740508 | 0.130 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 0.740508 | 0.130 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.740508 | 0.130 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.740508 | 0.130 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 0.740508 | 0.130 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.741976 | 0.130 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.749848 | 0.125 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.749848 | 0.125 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.749848 | 0.125 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.749848 | 0.125 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.749848 | 0.125 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.749848 | 0.125 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.751043 | 0.124 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.751043 | 0.124 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.751043 | 0.124 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.751043 | 0.124 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.751043 | 0.124 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.751043 | 0.124 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.754704 | 0.122 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.754704 | 0.122 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.754704 | 0.122 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.754704 | 0.122 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.758470 | 0.120 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.760461 | 0.119 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.760621 | 0.119 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.762079 | 0.118 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.762560 | 0.118 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.762560 | 0.118 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.762560 | 0.118 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.764356 | 0.117 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 0.764356 | 0.117 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 0.764356 | 0.117 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.764356 | 0.117 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.764393 | 0.117 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.765627 | 0.116 | 1 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.768039 | 0.115 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.768039 | 0.115 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 0.768039 | 0.115 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 0.768039 | 0.115 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.768039 | 0.115 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.768847 | 0.114 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.768847 | 0.114 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.768847 | 0.114 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.768847 | 0.114 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.770954 | 0.113 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.770954 | 0.113 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.771638 | 0.113 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.771638 | 0.113 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.777453 | 0.109 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.780950 | 0.107 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.781064 | 0.107 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.781317 | 0.107 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.782316 | 0.107 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.782316 | 0.107 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.782316 | 0.107 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.782316 | 0.107 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.783970 | 0.106 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.784015 | 0.106 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.784015 | 0.106 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.784015 | 0.106 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.784015 | 0.106 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.784015 | 0.106 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 0.784015 | 0.106 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.786014 | 0.105 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.786014 | 0.105 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.786014 | 0.105 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.786014 | 0.105 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.786014 | 0.105 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.786014 | 0.105 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.786014 | 0.105 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 0.786014 | 0.105 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.786466 | 0.104 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.788762 | 0.103 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.790701 | 0.102 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.790887 | 0.102 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.792789 | 0.101 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.799015 | 0.097 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.799015 | 0.097 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.799015 | 0.097 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.799015 | 0.097 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.799015 | 0.097 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.799015 | 0.097 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.802774 | 0.095 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.802774 | 0.095 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 0.805682 | 0.094 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 0.805682 | 0.094 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 0.805682 | 0.094 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.805682 | 0.094 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 0.805682 | 0.094 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 0.805682 | 0.094 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.805682 | 0.094 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.805682 | 0.094 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.806988 | 0.093 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.812002 | 0.090 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.813084 | 0.090 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.813084 | 0.090 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.813084 | 0.090 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.813084 | 0.090 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.814763 | 0.089 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.815570 | 0.089 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.817644 | 0.087 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.818871 | 0.087 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.818871 | 0.087 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.818871 | 0.087 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.823256 | 0.084 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 0.823544 | 0.084 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 0.823544 | 0.084 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.823544 | 0.084 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 0.823544 | 0.084 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.826266 | 0.083 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.826266 | 0.083 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.826266 | 0.083 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.826266 | 0.083 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.828479 | 0.082 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.828479 | 0.082 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.828479 | 0.082 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.829659 | 0.081 | 1 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.829836 | 0.081 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.829836 | 0.081 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.829836 | 0.081 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.829836 | 0.081 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.829836 | 0.081 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.829836 | 0.081 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.837841 | 0.077 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.837841 | 0.077 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 0.838605 | 0.076 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.838605 | 0.076 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.838605 | 0.076 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.838605 | 0.076 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.838605 | 0.076 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.838605 | 0.076 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.839765 | 0.076 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 0.839765 | 0.076 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.839765 | 0.076 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.839765 | 0.076 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.839765 | 0.076 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.839765 | 0.076 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.839765 | 0.076 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.839765 | 0.076 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.839765 | 0.076 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.839765 | 0.076 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.839765 | 0.076 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.839765 | 0.076 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.839765 | 0.076 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.840227 | 0.076 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.840227 | 0.076 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.842243 | 0.075 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.846770 | 0.072 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.847086 | 0.072 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.847086 | 0.072 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.847086 | 0.072 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.847972 | 0.072 | 1 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.850064 | 0.071 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.850064 | 0.071 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.850064 | 0.071 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.850145 | 0.071 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.850145 | 0.071 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.850145 | 0.071 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.850145 | 0.071 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.850145 | 0.071 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.850145 | 0.071 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.850145 | 0.071 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.854495 | 0.068 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.854495 | 0.068 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 0.854495 | 0.068 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.854495 | 0.068 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 0.854495 | 0.068 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 0.854495 | 0.068 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.854495 | 0.068 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.854495 | 0.068 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.854698 | 0.068 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.855280 | 0.068 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.856480 | 0.067 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.859370 | 0.066 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.860927 | 0.065 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.862597 | 0.064 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.863385 | 0.064 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.863385 | 0.064 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.867872 | 0.062 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 0.867872 | 0.062 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 0.867872 | 0.062 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 0.867872 | 0.062 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 0.867872 | 0.062 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.867872 | 0.062 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.869354 | 0.061 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.869985 | 0.060 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.870995 | 0.060 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.870995 | 0.060 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.871742 | 0.060 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.874374 | 0.058 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.876306 | 0.057 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.876470 | 0.057 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.876470 | 0.057 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.876470 | 0.057 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.878432 | 0.056 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 0.880020 | 0.056 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.880020 | 0.056 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 0.880020 | 0.056 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.880020 | 0.056 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.880020 | 0.056 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.880020 | 0.056 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 0.880020 | 0.056 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.880388 | 0.055 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.884308 | 0.053 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.884308 | 0.053 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.884308 | 0.053 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.888799 | 0.051 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.888799 | 0.051 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.889145 | 0.051 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.889145 | 0.051 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.889145 | 0.051 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.890226 | 0.050 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.891052 | 0.050 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.891052 | 0.050 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.891052 | 0.050 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 0.891052 | 0.050 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.891052 | 0.050 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.891052 | 0.050 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.897304 | 0.047 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.897304 | 0.047 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.898663 | 0.046 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.899078 | 0.046 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.900635 | 0.045 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.900635 | 0.045 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.900635 | 0.045 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.901070 | 0.045 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.901070 | 0.045 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.901070 | 0.045 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 0.901070 | 0.045 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.901070 | 0.045 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.901070 | 0.045 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.901070 | 0.045 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 0.901070 | 0.045 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.901070 | 0.045 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.901332 | 0.045 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.904258 | 0.044 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.904900 | 0.043 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.904900 | 0.043 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.904900 | 0.043 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.904900 | 0.043 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 0.904900 | 0.043 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.904900 | 0.043 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.905637 | 0.043 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.909790 | 0.041 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.910167 | 0.041 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.910167 | 0.041 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.910167 | 0.041 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.910167 | 0.041 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.910167 | 0.041 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.910167 | 0.041 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.910167 | 0.041 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.911968 | 0.040 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 0.911968 | 0.040 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.914380 | 0.039 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.916046 | 0.038 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.918287 | 0.037 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.918429 | 0.037 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.918429 | 0.037 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.918429 | 0.037 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 0.918429 | 0.037 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.918429 | 0.037 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.918542 | 0.037 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.918542 | 0.037 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 0.918542 | 0.037 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.919933 | 0.036 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.924651 | 0.034 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.925113 | 0.034 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.925636 | 0.034 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.925931 | 0.033 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.925931 | 0.033 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.925931 | 0.033 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 0.925931 | 0.033 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.925931 | 0.033 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 0.925931 | 0.033 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.925931 | 0.033 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.930326 | 0.031 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.930326 | 0.031 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.930326 | 0.031 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.930326 | 0.031 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.932743 | 0.030 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.932743 | 0.030 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.932743 | 0.030 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.933912 | 0.030 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.933912 | 0.030 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.934044 | 0.030 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.934044 | 0.030 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.935595 | 0.029 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.935595 | 0.029 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.937084 | 0.028 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.937103 | 0.028 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.937820 | 0.028 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.938929 | 0.027 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.938929 | 0.027 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.938929 | 0.027 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.938933 | 0.027 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.939813 | 0.027 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.940484 | 0.027 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.940484 | 0.027 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.940484 | 0.027 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.940632 | 0.027 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.941337 | 0.026 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.941582 | 0.026 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.941771 | 0.026 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.944081 | 0.025 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 0.944547 | 0.025 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.944547 | 0.025 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.944547 | 0.025 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 0.944547 | 0.025 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.944547 | 0.025 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.944547 | 0.025 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.945020 | 0.025 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.945020 | 0.025 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.948044 | 0.023 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.948630 | 0.023 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.948768 | 0.023 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.949225 | 0.023 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.949225 | 0.023 | 1 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 0.949648 | 0.022 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 0.949648 | 0.022 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 0.949648 | 0.022 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.949648 | 0.022 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.949648 | 0.022 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 0.949648 | 0.022 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 0.949648 | 0.022 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.949648 | 0.022 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.949648 | 0.022 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.949648 | 0.022 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.951908 | 0.021 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.952997 | 0.021 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.953122 | 0.021 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.953122 | 0.021 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.953263 | 0.021 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.954280 | 0.020 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.954280 | 0.020 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.954280 | 0.020 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.954280 | 0.020 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.954280 | 0.020 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.954986 | 0.020 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.955467 | 0.020 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.956732 | 0.019 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.956732 | 0.019 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.956732 | 0.019 | 1 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.958098 | 0.019 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.958487 | 0.018 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 0.958487 | 0.018 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.958487 | 0.018 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 0.958487 | 0.018 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.958487 | 0.018 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.958487 | 0.018 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.958487 | 0.018 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.958929 | 0.018 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.960074 | 0.018 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.962306 | 0.017 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.962306 | 0.017 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 0.962306 | 0.017 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.962306 | 0.017 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.963169 | 0.016 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.964749 | 0.016 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.965385 | 0.015 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.965385 | 0.015 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.965493 | 0.015 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.965493 | 0.015 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.965493 | 0.015 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 0.965774 | 0.015 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.965774 | 0.015 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.966032 | 0.015 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.966032 | 0.015 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.966364 | 0.015 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.966364 | 0.015 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.966808 | 0.015 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.967611 | 0.014 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.967632 | 0.014 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 0.968680 | 0.014 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.968924 | 0.014 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.968924 | 0.014 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.968924 | 0.014 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.969702 | 0.013 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 0.971129 | 0.013 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.971557 | 0.013 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.971783 | 0.012 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.972948 | 0.012 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.973817 | 0.012 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.974380 | 0.011 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.974380 | 0.011 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.975103 | 0.011 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.975484 | 0.011 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.975484 | 0.011 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.976738 | 0.010 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 0.977416 | 0.010 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.977416 | 0.010 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.977416 | 0.010 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.977978 | 0.010 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.978879 | 0.009 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.979200 | 0.009 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.980146 | 0.009 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.980146 | 0.009 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.980823 | 0.008 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.980823 | 0.008 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.980823 | 0.008 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.980823 | 0.008 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 0.980823 | 0.008 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.980823 | 0.008 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.980823 | 0.008 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.980848 | 0.008 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.982588 | 0.008 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.982588 | 0.008 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.983042 | 0.007 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.984191 | 0.007 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.984191 | 0.007 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.984693 | 0.007 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.984743 | 0.007 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.984743 | 0.007 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.985065 | 0.007 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.985647 | 0.006 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.985647 | 0.006 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 0.985647 | 0.006 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.985647 | 0.006 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 0.985647 | 0.006 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.985647 | 0.006 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.985724 | 0.006 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.985724 | 0.006 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.985901 | 0.006 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.985901 | 0.006 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.986259 | 0.006 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 0.986968 | 0.006 | 0 | 0 |
| Depurination | R-HSA-73927 | 0.986968 | 0.006 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 0.986968 | 0.006 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 0.986968 | 0.006 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.987413 | 0.006 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 0.988168 | 0.005 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.988270 | 0.005 | 1 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.988373 | 0.005 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.988373 | 0.005 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.988432 | 0.005 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.989223 | 0.005 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 0.989257 | 0.005 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 0.989257 | 0.005 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.989257 | 0.005 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.989308 | 0.005 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.989308 | 0.005 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.989308 | 0.005 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.990247 | 0.004 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.990247 | 0.004 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.990318 | 0.004 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.991145 | 0.004 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.991960 | 0.004 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.991960 | 0.004 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.991960 | 0.004 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.992234 | 0.003 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.992367 | 0.003 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.992980 | 0.003 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.993373 | 0.003 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.993373 | 0.003 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.993924 | 0.003 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.993967 | 0.003 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.993983 | 0.003 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.993983 | 0.003 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.994538 | 0.002 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.994538 | 0.002 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.994538 | 0.002 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.994538 | 0.002 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.994905 | 0.002 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.995030 | 0.002 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 0.995041 | 0.002 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.995205 | 0.002 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.995498 | 0.002 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.995498 | 0.002 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.995498 | 0.002 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.995791 | 0.002 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.995791 | 0.002 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.995913 | 0.002 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.996618 | 0.001 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.996631 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.996631 | 0.001 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.996631 | 0.001 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.996860 | 0.001 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.996860 | 0.001 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.996860 | 0.001 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.996867 | 0.001 | 1 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.996958 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.997014 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.997057 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.997169 | 0.001 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.997223 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.997223 | 0.001 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.997525 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.997695 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.997712 | 0.001 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.997715 | 0.001 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.997720 | 0.001 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.998055 | 0.001 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.998207 | 0.001 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.998222 | 0.001 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.998573 | 0.001 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.998589 | 0.001 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.998589 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.998589 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.998719 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.998719 | 0.001 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.998837 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.998945 | 0.000 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.998985 | 0.000 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.999042 | 0.000 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.999079 | 0.000 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.999142 | 0.000 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.999210 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.999349 | 0.000 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.999470 | 0.000 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.999470 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999513 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.999521 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.999537 | 0.000 | 1 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.999586 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 0.999599 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.999633 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 0.999636 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.999636 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999717 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.999718 | 0.000 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.999753 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999815 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999862 | 0.000 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.999890 | 0.000 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.999890 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999903 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 0.999915 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.999935 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.999938 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 0.999952 | 0.000 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.999960 | 0.000 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.999964 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999968 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999970 | 0.000 | 1 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.999973 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.999975 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.999978 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.999991 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 0.999993 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999993 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.999993 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.999996 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.999998 | 0.000 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.999998 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.999999 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 0.999999 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999999 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.999999 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 0.999999 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 0.999999 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 0.999999 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 1.000000 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.000000 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 1.000000 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 1.000000 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | 0.000 | 1 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 1 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | 0.000 | 1 | 0 |
| Innate Immune System | R-HSA-168249 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | -0.000 | 0 | 0 |